Patent Grant
12336837
The present disclosure provides methods of transferring and handling patient information, in particular information related to the risk of developing a pressure ulcer, to improve care when a patient receives care in multiple settings.
The skin is the largest organ in the human body. It is readily exposed to different kinds of damages and injuries. When the skin and its surrounding tissues are unable to redistribute external pressure and mechanical forces, ulcers may be formed. Prolonged continuous exposure to even modest pressure, such as the pressure created by the body weight of a supine patient on their posterior skin surfaces, may lead to a pressure ulcer. In the presence of other damage, such as the neuropathy and peripheral tissue weakening that can be induced by diabetes, even periodic exposure to moderate levels of pressure and stress may lead to an ulcer, for example a foot ulcer.
Pressure ulcers are developed by approximately 2.5 million people a year in the United States and an equivalent number in the European Union. In long-term and critical-care settings, up to 25% of elderly and immobile patients develop pressure ulcers. Approximately 60,000 U.S. patients die per year due to infection and other complications from pressure ulcers.
Detecting tissue damage before the skin breaks and intervening with the appropriate therapy to avoid further deterioration of the underlying tissue is desirable not only for the patient but society. The average cost of treating pressure-induced damage at the earliest visible sign (a Stage 1 ulcer) is only $2,000 but this rises to $129,000 when the ulcer is deep enough to expose muscle or bone (a Stage 4 ulcer.) Currently, patients normally receive universal prevention of pressure ulcers, meaning that the prevention does not target to any particular anatomical sites. Patients only receive a targeted, localized, treatment of ulcer after the pressure ulcer is developed to the point that it can be identified by a visual assessment. The current standard to detect pressure ulcers is by visual inspection, which is subjective, unreliable, untimely, and lacks specificity. Therefore, even when a patient is experiencing inflammation of the skin, a precursor of ulcer development, he or she would not be receiving a targeted, localized treatment for the developing ulcer. Instead, the inflammation would continue to develop into a full-blown ulcer.
In current practice, an independent assessment of a patient's risk of developing a pressure ulcer is performed upon arrive in a care setting. This lack of knowledge from the prior care setting may diminish the quality of care received at the new care setting.
In one aspect, the present disclosure provides for, and includes, a method of identifying and providing an appropriate level of pressure ulcer care to a patient based on a plurality of Sub-Epidermal Moisture (SEM) measurements. In an aspect, a patient is provided with increasingly effective pressure ulcer interventions based on changes in SEM measurements. In an aspect, a patient is given less intensive pressure ulcer interventions based on changes in SEM measurements.
A method of providing a continuity of care for a patient during transfer between care settings, the method comprising the steps of: deciding to transfer a patient from a first care setting to a second care setting, performing a first assessment of the patient in the first care setting, preparing a transfer record of the assessment, and transferring the transfer record with the patient to the second care setting.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of pressure ulcer treatment, the method comprising the steps of: evaluating a patient for a risk of pressure ulcer in a patient upon admission to a care facility, where the evaluating step comprises making a first plurality of Sub-Epidermal Moisture (SEM) measurements in the patient, calculating a first delta value from a portion of the first plurality of SEM measurements, determining whether the first delta value exceeds a first threshold, administering a first intervention of level-0 if the first delta value does not exceed the first threshold, and administering a first intervention of level-N if the first delta value exceeds the first threshold, where N is an integer and N has a value of 1 or greater. In a further aspect, the present disclosure provides for, and includes, making a second plurality of SEM measurements in the patient at a first pre-determined frequency corresponding to the administered intervention level, calculating a second delta value from a portion of the second plurality of SEM measurements, determining whether the second delta value exceeds a second threshold, continuing to administer the first intervention if the second delta value does not exceed the second threshold, continuing to make a plurality of SEM measurements at the first pre-determined frequency if the second delta value does not exceed the second threshold, administering a second intervention of level-M if the second delta value exceeds the second threshold, where M is an integer and M is greater than N, and making a plurality of SEM measurements at a second pre-determined frequency corresponding to level-M if the second delta value exceeds the second threshold. In yet a further aspect, the present disclosure provides for, and includes, determining whether the second delta value is less than a third threshold, administering a level-(N−1) intervention if the second delta value is less than the third threshold and if the first intervention is not of level-0, and making a plurality of SEM measurements at a pre-determined frequency corresponding to level-(N−1) if the second delta value is less than the third threshold.
In one aspect, the present disclosure provides for, and includes, a method of slowing the progression of pressure ulcer development in a patient in need thereof, the method comprising the steps of: identifying a current intervention of level-K received by the patient, making a plurality of Sub-Epidermal Moisture (SEM) measurements in the patient, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a first threshold, continuing to administer the current intervention if the delta value does not exceed the first threshold, continuing to make a plurality of SEM measurements at a pre-determined frequency corresponding to level-K if the delta value does not exceed the first threshold, administering a new intervention of level-N if the delta value exceeds the first threshold, where N has a value greater than K, and making a plurality of SEM measurements at a pre-determined frequency corresponding to level-N if the delta value exceeds the first threshold. In a further aspect, the present disclosure provides for, and includes, determining whether the delta value is less than a second threshold, administering a level-L intervention if the delta value is less than the second threshold, where L has a non-negative value less than K, and making a plurality of SEM measurements at a pre-determined frequency corresponding to level-L if the delta value is less than the second threshold.
In an aspect, the present disclosure provides for, and includes, a method of stratifying groups of patients in a care facility based on pressure ulcer risk, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements in each of the patients, calculating a delta value from a portion of the plurality of SEM measurements for each of the patients, determining whether each delta value exceeds any values in a set of threshold values corresponding to N care levels and assigning a care level to each of the patients, rearranging the group of patients based on each of the patient's assigned care levels.
In one aspect, the present disclosure provides for, and includes, a method of reducing incidence of pressure ulcer in patients admitted to a care facility, the method comprising the steps of: evaluating a patient for a risk of pressure ulcer upon admission to the care facility, where the evaluating step comprises making a first plurality of Sub-Epidermal Moisture (SEM) measurements in the patient, calculating a first delta value from a portion of the first plurality of SEM measurements, determining whether the first delta value exceeds a first threshold, administering a first intervention of level-0 if the first delta value does not exceed the first threshold, and administering a & intervention of level-N if the first delta value exceeds the first threshold, where N is an integer and N has a value of 1 or greater.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a barrier cream to the patient's heel, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's heel, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a barrier cream to the patient's heel if the delta value exceeds the threshold, and making a plurality of SEM measurements every two hours if the delta value exceeds the threshold.
In one aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a neuro-muscular stimulation to the patient's heel, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's heel, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a neuro-muscular stimulation to the patient's heel if the delta value exceeds the threshold, and making a plurality of SEM measurements every hour if the delta value exceeds the threshold.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a topical cream to the patient's heel, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's heel, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a topical cream to the patient's heel if the delta value exceeds the threshold, and making a plurality of SEM measurements every half an hour if the delta value exceeds the threshold.
In one aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a barrier cream to the patient's sacrum, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's sacrum, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a barrier cream to the patient's sacrum if the delta value exceeds the threshold, and making a plurality of SEM measurements every six hours if the delta value exceeds the threshold.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a neuro-muscular stimulation to the patient's sacrum, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's sacrum, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a neuro-muscular stimulation to the patient's sacrum if the delta value exceeds the threshold, and making a plurality of SEM measurements every four hours if the delta value exceeds the threshold.
In one aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a topical cream to the patient's sacrum, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's sacrum, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a topical cream to the patient's sacrum if the delta value exceeds the threshold, and making a plurality of SEM measurements every two hours if the delta value exceeds the threshold.
Aspects of the disclosure are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and are for purposes of illustrative discussion of aspects of the disclosure. In this regard, the description and the drawings, considered alone and together, make apparent to those skilled in the art how aspects of the disclosure may be practiced.
This description is not intended to be a detailed catalog of all the different ways in which the disclosure may be implemented, or all the features that may be added to the instant disclosure. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Thus, the disclosure contemplates that in some embodiments of the disclosure, any feature or combination of features set forth herein can be excluded or omitted. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant disclosure. In other instances, well-known structures, interfaces, and processes have not been shown in detail in order not to unnecessarily obscure the invention. It is intended that no part of this specification be construed to effect a disavowal of any part of the full scope of the invention. Hence, the following descriptions are intended to illustrate some particular embodiments of the disclosure, and not to exhaustively specify all permutations, combinations and variations thereof.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description of the disclosure herein is for the purpose of describing particular aspects or embodiments only and is not intended to be limiting of the disclosure.
All publications, patent applications, patents and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented. References to techniques employed herein are intended to refer to the techniques as commonly understood in the art, including variations on those techniques or substitutions of equivalent techniques that would be apparent to one of skill in the art.
U.S. patent application Ser. No. 14/827,375 (“the '375 application”) discloses an apparatus that uses radio frequency (RF) energy to measure the sub-epidermal capacitance using a bipolar sensor, where the sub-epidermal capacitance corresponds to the moisture content of the target region of skin of a patient. The '375 application also discloses an array of these bipolar sensors of various sizes.
U.S. patent application Ser. No. 15/134,110 discloses an apparatus for measuring sub-epidermal moisture (SEM) similar to the device shown in
Both U.S. patent application Ser. Nos. 14/827,375 and 15/134,110 are incorporated herein by reference in their entireties. However, the SEM values of this application may be measured by any similar or equivalent devices or techniques that would be apparent to one of skill in the art. For example, a device measuring the SEM values of this application may be a wired device, a wireless device, or a system comprising various components in communication with each other.
Unless the context indicates otherwise, it is specifically intended that the various features of the disclosure described herein can be used in any combination. Moreover, the present disclosure also contemplates that in some embodiments of the disclosure, any feature or combination of features set forth herein can be excluded or omitted.
The methods disclosed herein include and comprise one or more steps or actions for achieving the described method. The method steps and/or actions may be interchanged with one another without departing from the scope of the present disclosure. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified without departing from the scope of the present disclosure.
As used in the description of the disclosure and the appended claims, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
As used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
The terms “about” and “approximately” as used herein when referring to a measurable value such as a length, a frequency, or a SEM value and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount.
As used herein, phrases such as “between X and Y” and “between about X and Y” should be interpreted to include X and Y. As used herein, phrases such as “between about X and Y” mean “between about X and about Y” and phrases such as “from about X to Y” mean “from about X to about Y.”
As used herein, the term “sub-epidermal moisture” or “SEM” refers to the increase in tissue fluid and local edema caused by vascular leakiness and other changes that modify the underlying structure of the damaged tissue in the presence of continued pressure on tissue, apoptosis, necrosis, and the inflammatory process.
As used herein, a “patient” may be a human or animal subject.
As used herein, “delta” refers to a calculated difference between two SEM values.
As used herein, the variables “K,” “L,” “M,” and “N” are non-negative integers.
In an aspect, in process 100, a newly admitted patient receives an intake evaluation in step 104 that includes one or more of a visual examination of a portion of the patient's skin, completion of at least a portion of a risk assessment protocol that evaluates one or more of nutrition, mobility, physical activity, physical strength, and ability to communicate, and SEM measurements made in one or more locations on the patient's skin. In an aspect, the SEM measurements may include making a plurality of SEM measurements at a single “location” on the patient's skin. In one aspect, “location” is considered as an area rather than a single point such that SEM measurements may be made at spatially separated points within the location. For example, a “heel” location includes the medial, lateral, and posterior surfaces around the heel as well as the posterior portion of the sole of that foot.
In one aspect, once the evaluation step is complete, a determination is made in step 106 as to whether the patient is “deviated,” i.e., whether the combination of the results of the various elements of the evaluation indicate that the patient has, or is at risk of developing, tissue damage that could lead to a pressure ulcer. Each element of the evaluation may have an individual criterion for level of risk, for example a scoring system with threshold value that indicates an unacceptable risk. In an aspect, there is a protocol to combine the criteria to generate a composite parameter that can be used to select a level of intervention.
In an aspect, if the patient is determined to be at an acceptable level of risk, the process branches to step 108 which implements the lowest level of intervention, designated herein as “level-zero” or “level-0.” Progressing through steps 110 and 112, the patient will be re-assessed using at least the SEM measurement protocol in step 114 at a frequency, or conversely a time interval, associated with level-0. The process 100 then loops back to step 106 to evaluate the results of the SEM measurements made in step 114.
In one aspect, if the patient is determined in step 106 to be deviated, then the process branches to step 122, which implements a higher level of intervention. In an aspect, there is a defined hierarchy of intervention levels, with each level implementing a more effective intervention than the next-lower level. In an aspect, each level also has a defined monitoring interval or frequency indicating how often a set of SEM measurements should be made, where higher levels will generally have shorter intervals. In this example, the process has been defined by the hospital, or other administering organization, to step up one level to a level-1 intervention at this point. In another aspect, step 122 may implement a level-2 or higher level of intervention. The process now enters a new loop starting at step 130 where the patient will now be monitored at a level-N frequency where N is in the range of 1 to n, n being the highest defined level of intervention and monitoring.
In an aspect, at step 134, the patient's history is evaluated to determine whether their condition is improving. If the patient's condition is improving, for example as evidenced by a decreasing delta value, then the process branches to step 142. In this example, step 142 continues to implement the current level of intervention and the process loops through step 140 to steps 130-132-134-142-140 until the delta value drops below the threshold. In an aspect, the level of intervention may be reduced in step 142 based on the magnitude of the delta value as the delta value trends downward.
In one aspect, if the patient does not show improvement in step 134, the process branches to an increase in the level of intervention in step 138 provided that the skin is not broken, i.e., an open ulcer has not developed, in step 136. If an open ulcer has developed, the SEM scanning will now be performed around the periphery of the open wound in step 144 to map inflammation or other precursor indication of the ulcer spreading. The ulcer itself is treated in step 148 and this secondary loop 144-146-148-150 continues until the wound closes, whereupon the process returns to step 130.
In an aspect, at any time in process 100, discharge of the patient branches to step 118, where the condition of the patient upon discharge or transfer is documented. In an aspect, step 118 comprises a final set of SEM measurements at one of more locations on the patient's body. In an aspect, these locations include areas that were not receiving an intervention and were not previously identified as at risk. In an aspect, this information is provided to the receiving caregiver. The patient is then discharged or transferred in step 120.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of pressure ulcer treatment, the method comprising the steps of: evaluating a patient for a risk of pressure ulcer in a patient upon admission to a care facility, where the evaluating step comprises making a first plurality of Sub-Epidermal Moisture (SEM) measurements in the patient, calculating a first delta value from a portion of the first plurality of SEM measurements, determining whether the first delta value exceeds a first threshold, administering a first intervention of level-0 if the first delta value does not exceed the first threshold, and administering a first intervention of level-N if the first delta value exceeds the first threshold, where N is an integer and N has a value of 1 or greater.
In one aspect, a first plurality of SEM measurements is taken at and around one or more anatomical sites selected from the group consisting of a sternum, a sacrum, a heel, a scapula, an elbow, an ear, and other fleshy tissues of a patient. In an aspect, a first plurality of SEM measurements is separated into sub-groups for analysis based on the general location at which a measurement is taken. In one aspect, a first plurality of SEM measurements is taken at locations located on one or more concentric circles centered around an anatomical site. In an aspect, a first plurality of SEM measurements is taken at locations located on a straight line at approximately equidistance from an anatomical site.
In one aspect, a first delta value is determined by the difference between the maximum SEM value and the minimum SEM value from the first plurality of SEM measurements collected. In an aspect, a first delta value is determined by the difference between the maximum SEM average of measurements taken at one location and the minimum SEM average of measurements taken at a second location. In one aspect, a first delta value is determined for a portion of a first plurality of SEM measurements made up of a sub-group as defined by location taken. In an aspect, an average SEM value at a location is obtained from two, three, four, five, six, seven, eight, nine, ten, or more than ten SEM values measured at that location. In one aspect, a first delta value is determined by the difference between SEM values derived from measurements taken at two bisymmetric locations with respect to a centerline.
In an aspect, a delta value may be calculated from a plurality of SEM measurements made at a certain location, or in close proximity around a specific location, in a plurality of methods. In an aspect, a plurality of SEM measurements are made in a pre-determined pattern on the skin and the delta value is calculated by subtracting the SEM value associated with a pre-determined position within the pattern from the largest SEM value made at the other positions in the pattern. In an aspect, a plurality of SEM measurements are made in a pre-determined pattern on the skin and the delta value is calculated by identifying the SEM value associated with a pre-determined position within the pattern and subtracting the largest SEM value made at the other positions in the pattern. In an aspect, an average SEM value may be calculated from a portion of a set of SEM values generated by a plurality of SEM measurements at a single location and a delta value calculated as the largest difference between the average and a single SEM value of the same set. In an aspect, a delta value may be calculated as a ratio of the largest SEM value to the smallest SEM value within a set of SEM values.
In an aspect, a first threshold may be about 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5. In one aspect, a first threshold may range from 0.1 to 8.0, such as from 0.1 to 1.0, from 1.1 to 2.0, from 2.1 to 3.0, from 3.1 to 4.0, from 4.1 to 5.0, from 5.1 to 6.0, from 6.1 to 7.0, from 7.1 to 8.0, from 0.1 to 7.5, from 0.5 to 8.0, from 1.0 to 7.0, from 1.5 to 6.5, from 2.0 to 6.0, from 3.0 to 5.5, from 3.5 to 5.0, or from 4.0 to 4.5. In an aspect, a first threshold can be scaled by a factor or a multiple based on the values provided herein. It will be understood that a threshold is not limited by design, but rather, one of ordinary skill in the art would be capable of choosing a predetermined value based on a given unit of SEM. In one aspect, thresholds of the present disclosure are varied according to the specific portion of a patient's body on which measurements are being made, or one or more characteristics of the patient such as age, height, weight, family history, ethnic group, and other physical characteristics or medical conditions.
In an aspect, N ranges from 1 to 50, such as from 1 to 2, from 1 to 3, from 1 to 4, from 1 to 5, from 1 to 6, from 1 to 7, from 1 to 8, from 1 to 9, from 1 to 10, from 1 to 15, from 1 to 20, from 1 to 25, from 1 to 30, from 1 to 35, from 1 to 40, or from 1 to 45.
In one aspect, N is determined by the amount by which the first delta value exceeds the first threshold. In an aspect, the amount by which a delta value exceeds a threshold established for (N+1) is greater than the amount by which a delta value exceeds a threshold established for N. In one aspect, the amount by which a delta value exceeds a threshold established for (N−1) is less than the amount by which a delta value exceeds a threshold established for N.
In an aspect, a level-1 (N=1) intervention is applied to a patient having a delta value exceeding the threshold by not more than 100% of the threshold value, such as not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In an aspect, a level-2 (N=2) intervention is applied to a patient having a delta value exceeding the threshold by not more than 150% of the threshold value, such as not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-3 (N=3) intervention is applied to a patient having a delta value exceeding the threshold by not more than 200% of the threshold value, such as not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-4 (N=4) intervention is applied to a patient having a delta value exceeding the threshold by not more than 250% of the threshold value, such as not more than 245%, not more than 240%, not more than 235%, not more than 230%, not more than 225%, not more than 220%, not more than 215%, not more than 210%, not more than 205%, not more than 200%, not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-5 (N=5) intervention is applied to a patient having a delta value exceeding the threshold by not more than 300% of the threshold value, such as not more than 295%, not more than 290%, not more than 285%, not more than 280%, not more than 275%, not more than 270%, not more than 265%, not more than 260%, not more than 255%, not more than 250%, not more than 245%, not more than 240%, not more than 235%, not more than 230%, not more than 225%, not more than 220%, not more than 215%, not more than 210%, not more than 205%, not more than 200%, not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-6 (N=6) intervention is applied to a patient having a delta value exceeding the threshold by not more than 350% of the threshold value, such as not more than 345%, not more than 340%, not more than 335%, not more than 330%, not more than 325%, not more than 320%, not more than 315%, not more than 310%, not more than 305%, not more than 300%, not more than 295%, not more than 290%, not more than 285%, not more than 280%, not more than 275%, not more than 270%, not more than 265%, not more than 260%, not more than 255%, not more than 250%, not more than 245%, not more than 240%, not more than 235%, not more than 230%, not more than 225%, not more than 220%, not more than 215%, not more than 210%, not more than 205%, not more than 200%, not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-7 (N=7) intervention is applied to a patient having a delta value exceeding the threshold by not more than 400% of the threshold value, such as not more than 395%, not more than 390%, not more than 385%, not more than 380%, not more than 375%, not more than 370%, not more than 365%, not more than 360%, not more than 355%, not more than 350%, not more than 345%, not more than 340%, not more than 335%, not more than 330%, not more than 325%, not more than 320%, not more than 315%, not more than 310%, not more than 305%, not more than 300%, not more than 295%, not more than 290%, not more than 285%, not more than 280%, not more than 275%, not more than 270%, not more than 265%, not more than 260%, not more than 255%, not more than 250%, not more than 245%, not more than 240%, not more than 235%, not more than 230%, not more than 225%, not more than 220%, not more than 215%, not more than 210%, not more than 205%, not more than 200%, not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-8 (N=8) intervention is applied to a patient having a delta value exceeding the threshold by not more than 450% of the threshold value, such as not more than 445%, not more than 440%, not more than 435%, not more than 430%, not more than 425%, not more than 420%, not more than 415%, not more than 410%, not more than 405%, not more than 400%, not more than 395%, not more than 390%, not more than 385%, not more than 380%, not more than 375%, not more than 370%, not more than 365%, not more than 360%, not more than 355%, not more than 350%, not more than 345%, not more than 340%, not more than 335%, not more than 330%, not more than 325%, not more than 320%, not more than 315%, not more than 310%, not more than 305%, not more than 300%, not more than 295%, not more than 290%, not more than 285%, not more than 280%, not more than 275%, not more than 270%, not more than 265%, not more than 260%, not more than 255%, not more than 250%, not more than 245%, not more than 240%, not more than 235%, not more than 230%, not more than 225%, not more than 220%, not more than 215%, not more than 210%, not more than 205%, not more than 200%, not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-9 (N=9) intervention is applied to a patient having a delta value exceeding the threshold by not more than 500% of the threshold value, such as not more than 495%, not more than 490%, not more than 485%, not more than 480%, not more than 475%, not more than 470%, not more than 465%, not more than 460%, not more than 455%, not more than 450%, not more than 445%, not more than 440%, not more than 435%, not more than 430%, not more than 425%, not more than 420%, not more than 415%, not more than 410%, not more than 405%, not more than 400%, not more than 395%, not more than 390%, not more than 385%, not more than 380%, not more than 375%, not more than 370%, not more than 365%, not more than 360%, not more than 355%, not more than 350%, not more than 345%, not more than 340%, not more than 335%, not more than 330%, not more than 325%, not more than 320%, not more than 315%, not more than 310%, not more than 305%, not more than 300%, not more than 295%, not more than 290%, not more than 285%, not more than 280%, not more than 275%, not more than 270%, not more than 265%, not more than 260%, not more than 255%, not more than 250%, not more than 245%, not more than 240%, not more than 235%, not more than 230%, not more than 225%, not more than 220%, not more than 215%, not more than 210%, not more than 205%, not more than 200%, not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-10 (N=10) intervention is applied to a patient having a delta value exceeding the threshold by not more than 550% of the threshold value, such as not more than 545%, not more than 540%, not more than 535%, not more than 530%, not more than 525%, not more than 520%, not more than 515%, not more than 510%, not more than 505%, not more than 500%, not more than 495%, not more than 490%, not more than 485%, not more than 480%, not more than 475%, not more than 470%, not more than 465%, not more than 460%, not more than 455%, not more than 450%, not more than 445%, not more than 440%, not more than 435%, not more than 430%, not more than 425%, not more than 420%, not more than 415%, not more than 410%, not more than 405%, not more than 400%, not more than 395%, not more than 390%, not more than 385%, not more than 380%, not more than 375%, not more than 370%, not more than 365%, not more than 360%, not more than 355%, not more than 350%, not more than 345%, not more than 340%, not more than 335%, not more than 330%, not more than 325%, not more than 320%, not more than 315%, not more than 310%, not more than 305%, not more than 300%, not more than 295%, not more than 290%, not more than 285%, not more than 280%, not more than 275%, not more than 270%, not more than 265%, not more than 260%, not more than 255%, not more than 250%, not more than 245%, not more than 240%, not more than 235%, not more than 230%, not more than 225%, not more than 220%, not more than 215%, not more than 210%, not more than 205%, not more than 200%, not more than 195%, not more than 190%, not more than 185%, not more than 180%, not more than 175%, not more than 170%, not more than 165%, not more than 160%, not more than 155%, not more than 150%, not more than 145%, not more than 140%, not more than 135%, not more than 130%, not more than 125%, not more than 120%, not more than 115%, not more than 110%, not more than 100%, not more than 95%, not more than 90%, not more than 85%, not more than 80%, not more than 75%, not more than 70%, not more than 65%, not more than 60%, not more than 55%, not more than 50%, not more than 45%, not more than 40%, not more than 35%, not more than 30%, not more than 25%, not more than 20%, not more than 15%, not more than 10%, or not more than 5% of the threshold value.
In one aspect, a level-N intervention is more effective than a level-0 intervention. In an aspect, a level-(N+1) intervention is more effective than a level-N intervention. In one aspect, a level-(N−1) intervention is less effective than a level-N intervention.
In an aspect, the evaluating step of the present disclosure further comprises performing a visual assessment. In one aspect, the visual assessment is performed in accordance with the guidelines of the National Pressure Ulcer Advisory Panel (NPUAP).
In one aspect, the evaluating step of the present disclosure further comprises performing a risk assessment. In an aspect, the risk assessment is performed in accordance with a test selected from the group consisting of the Braden Scale, the Gosnell Scale, the Norton Scale, and the Waterlow Scale.
In an aspect, the present disclosure further provides for, and includes, making a second plurality of SEM measurements in the patient at a first pre-determined frequency corresponding to the administered intervention level, calculating a second delta value from a portion of the second plurality of SEM measurements, determining whether the second delta value exceeds a second threshold, continuing to administer the first intervention if the second delta value does not exceed the second threshold, continuing to make a plurality of SEM measurements at the first pre-determined frequency if the second delta value does not exceed the second threshold, administering a second intervention of level-M if the second delta value exceeds the second threshold, where M is an integer and M is greater than N, and making a plurality of SEM measurements at a second pre-determined frequency corresponding to level-M if the second delta value exceeds the second threshold.
In one aspect, a pre-determined frequency is selected from the group consisting of at least once every 72 hours, at least once every 48 hours, at least once every 24 hours, at least once every 12 hours, at least once every 8 hours, at least once every 6 hours, at least once every 4 hours, at least once every 3 hours, at least once every 2 hours, at least once every hour, and at least once every half an hour.
In one aspect, a second plurality of SEM measurements are taken in accordance with.
In an aspect, a second plurality of SEM measurements are made at the same locations where a first plurality of SEM measurements were taken. In one aspect, a second plurality of SEM measurements are made at some of the same locations where a first plurality of SEM measurements were taken. In an aspect, a second plurality of SEM measurements are made near the locations where a first plurality of SEM measurements were taken. In one aspect, a second plurality of SEM measurements are made at different locations than where a first plurality of SEM measurements were taken.
In an aspect, a second delta value is determined by the difference between the maximum SEM value and the minimum SEM value from the second plurality of SEM measurements collected. In one aspect, a second delta value is determined by the difference between the maximum SEM average of measurements taken at one location and the minimum SEM average of measurements taken at a second location. In one aspect, a second delta value is determined for a portion of a second plurality of SEM measurements made up of a sub-group as defined by location taken.
In an aspect, a second threshold may be about 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5. In one aspect, a second threshold may range from 0.1 to 8.0, such as from 0.1 to 1.0, from 1.1 to 2.0, from 2.1 to 3.0, from 3.1 to 4.0, from 4.1 to 5.0, from 5.1 to 6.0, from 6.1 to 7.0, from 7.1 to 8.0, from 0.1 to 7.5, from 0.5 to 8.0, from 1.0 to 7.0, from 1.5 to 6.5, from 2.0 to 6.0, from 3.0 to 5.5, from 3.5 to 5.0, or from 4.0 to 4.5. In an aspect, a second threshold can be scaled by a factor or a multiple based on the values provided herein. In one aspect, a second threshold can be the same as a first threshold. In an aspect, a second threshold can be greater than a first threshold. In one aspect, a second threshold can be less than a first threshold.
In an aspect, M ranges from 2 to 50, such as from 2 to 3, from 2 to 4, from 2 to 5, from 2 to 6, from 2 to 7, from 2 to 8, from 2 to 9, from 2 to 10, from 2 to 15, from 2 to 20, from 2 to 25, from 2 to 30, from 2 to 35, from 2 to 40, or from 2 to 45.
In one aspect, M is determined by the amount by which the second delta value exceeds the second threshold. In an aspect, the amount by which a delta value exceeds a threshold established for (M+1) is greater than the amount by which a delta value exceeds a threshold established for M. In one aspect, the amount by which a delta value exceeds a threshold established for (M−1) is less than the amount by which a delta value exceeds a threshold established for M.
In an aspect, a level M intervention is chosen in accordance with [0063] to [0072], replacing N with M.
In one aspect, the present disclosure further provides for, and includes, determining whether the second delta value is less than a third threshold, administering a level-(N−1) intervention if the second delta value is less than the third threshold and if the first intervention is not of level-0, and making a plurality of SEM measurements at a pre-determined frequency corresponding to level-(N−1) if the second delta value is less than the third threshold.
In an aspect, a third threshold may be about 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5. In one aspect, a third threshold may range from 0.1 to 8.0, such as from 0.1 to 1.0, from 1.1 to 2.0, from 2.1 to 3.0, from 3.1 to 4.0, from 4.1 to 5.0, from 5.1 to 6.0, from 6.1 to 7.0, from 7.1 to 8.0, from 0.1 to 7.5, from 0.5 to 8.0, from 1.0 to 7.0, from 1.5 to 6.5, from 2.0 to 6.0, from 3.0 to 5.5, from 3.5 to 5.0, or from 4.0 to 4.5. In an aspect, a third threshold can be scaled by a factor or a multiple based on the values provided herein. In one aspect, a third threshold can be the same as a second threshold. In an aspect, a third threshold can be greater than a second threshold. In one aspect, a third threshold can be less than a second threshold. In one aspect, a third threshold can be the same as a first threshold. In an aspect, a third threshold can be greater than a first threshold. In one aspect, a third threshold can be less than a first threshold.
In an aspect, a second delta value can be 0.1-99.5% of the third threshold, such as 0.1-1%, 0.1-5%, 1-5%, 5-15%, 10-20%, 15-25%, 20-30%, 25-35%, 30-40%, 35-45%, 40-50%, 0.1-25%, 15-35%, 25-50%, 25-75%, 45-55%, 50-60%, 55-65%, 60-70%, 65-75%, 40-55%, 50-75%, 50-99.5%, 70-80%, 75%-85%, 80-90%, 85-95%, 90-99.5%, 65-85%, or 75-99.5% of the third threshold.
In one aspect, the present disclosure provides for, and includes, a method of slowing the progression of pressure ulcer development in a patient in need thereof, the method comprising the steps of: identifying a current intervention of level-K received by the patient, making a plurality of Sub-Epidermal Moisture (SEM) measurements in the patient, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a first threshold, continuing to administer the current intervention if the delta value does not exceed the first threshold, continuing to make a plurality of SEM measurements at a pre-determined frequency corresponding to level-K if the delta value does not exceed the first threshold, administering a new intervention of level-N if the delta value exceeds the first threshold, where N has a value greater than K, and making a plurality of SEM measurements at a pre-determined frequency corresponding to level-N if the delta value exceeds the first threshold. In an aspect, a patient in need thereof is a patient experiencing a change of care, a change in mobility, a change in nutrition, a change in sensory perception, or a combination thereof. In one aspect, a patient in need thereof is a patient having developed an open ulcer. In an aspect, a patient in need thereof is a patient having recovered from an open ulcer. In one aspect, a patient in need thereof is a patient receiving surgery. In an aspect, a patient in need thereof is a patient receiving spinal analgesics or sacral analgesics during a surgery. In one aspect, a patient in need thereof is a patient receiving a surgery for a duration of four or more hours, such as five or more hours, six or more hours, seven or more hours, eight or more hours, nine or more hours, ten or more hours, eleven or more hours, or twelve or more hours. In an aspect, a surgery has a duration of one or more hours, such as two or more hours, or three or more hours.
In one aspect, a plurality of SEM measurements are taken in accordance with [0057]. In an aspect, a delta value is determined in accordance with [0058]. In one aspect, a first threshold is determined in accordance with [0060].
In an aspect, K ranges from 2 to 50, such as from 2 to 3, from 2 to 4, from 2 to 5, from 2 to 6, from 2 to 7, from 2 to 8, from 2 to 9, from 2 to 10, from 2 to 15, from 2 to 20, from 2 to 25, from 2 to 30, from 2 to 35, from 2 to 40, or from 2 to 45.
In an aspect, K is determined by the amount by which the delta value exceeds the threshold. In an aspect, the amount by which a delta value exceeds a threshold established for (K+1) is greater than the amount by which a delta value exceeds a threshold established for K. In one aspect, the amount by which a delta value exceeds a threshold established for (K−1) is less than the amount by which a delta value exceeds a threshold established for K.
In an aspect, a level K intervention is chosen in accordance with [0063] to [0072], replacing N with K.
In an aspect, the present disclosure further provides for, and includes, determining whether the delta value is less than a second threshold, administering a level-L intervention if the delta value is less than the second threshold, where L has a non-negative value less than K, and making a plurality of SEM measurements at a pre-determined frequency corresponding to level-L if the delta value is less than the second threshold.
In an aspect, a second threshold is determined in accordance with [0080].
In an aspect, L can be K−1, K−2, K−3, K−4, K−5, K−6, K−7, K−8, K−9, or K−10. In one aspect, L is K−1 if a delta value is 90-99.5% of the second threshold, such as 90-95%, 91-96%, 92-97%, 93-98%, 94-99%, or 95-99.5% of the second threshold, unless K−1 is less than 0, in which case L would be 0. In an aspect, L is K−2 if a delta value is 80-89.9% of the second threshold, such as 80-85%, 81-86%, 82-87%, 83-88%, 84-89%, or 85-89.9% of the second threshold, unless K−2 is less than 0, in which case L would be 0. In one aspect, L is K−3 if a delta value is 70-79.9% of the second threshold, such as 70-75%, 71-76%, 72-77%, 73-78%, 74-79%, or 75-79.9% of the second threshold, unless K−3 is less than 0, in which case L would be 0. In an aspect, L is K−4 if a delta value is 60-69.9% of the second threshold, such as 60-65%, 61-66%, 62-67%, 63-68%, 64-69%, or 65-69.9% of the second threshold, unless K−4 is less than 0, in which case L would be 0. In one aspect, L is K−5 if a delta value is 50-59.9% of the second threshold, such as 50-55%, 51-56%, 52-57%, 53-58%, 54-59%, or 55-59.9% of the second threshold, unless K−5 is less than 0, in which case L would be 0. In an aspect, L is K−6 if a delta value is 40-49.9% of the second threshold, such as 40-45%, 41-46%, 42-47%, 43-48%, 44-49%, or 45-49.9% of the second threshold, unless K−6 is less than 0, in which case L would be 0. In one aspect, L is K−7 if a delta value is 30-39.9% of the second threshold, such as 30-35%, 31-36%, 32-37%, 33-38%, 34-39%, or 35-39.9% of the second threshold, unless K−7 is less than 0, in which case L would be 0. In an aspect, L is K−8 if a delta value is 20-29.9% of the second threshold, such as 20-25%, 21-26%, 22-27%, 23-28%, 24-29%, or 25-29.9% of the second threshold, unless K−8 is less than 0, in which case L would be 0. In one aspect, L is K−9 if a delta value is 10-19.9% of the second threshold, such as 10-15%, 11-16%, 12-17%, 13-18%, 14-19%, or 15-19.9% of the second threshold, unless K−9 is less than 0, in which case L would be 0. In an aspect, L is K−10 if a delta value is 0.1-9.9% of the second threshold, such as 0.1-5%, 1-6%, 2-7%, 3-8%, 4-9%, or 5-9.9% of the second threshold, unless K−10 is less than 0, in which case L would be 0.
In an aspect, the present disclosure provides for, and includes, a method of stratifying groups of patients in a care facility based on pressure ulcer risk, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements in each of the patients, calculating a delta value from a portion of the plurality of SEM measurements for each of the patients, determining whether each delta value exceeds any values in a set of threshold values corresponding to N care levels and assigning a care level to each of the patients, rearranging the group of patients based on each of the patient's assigned care levels.
In one aspect, the present disclosure provides for, and includes, a method of reducing incidence of pressure ulcer in patients admitted to a care facility, the method comprising the steps of: evaluating a patient for a risk of pressure ulcer upon admission to the care facility, where the evaluating step comprises making a first plurality of Sub-Epidermal Moisture (SEM) measurements in the patient, calculating a first delta value from a portion of the first plurality of SEM measurements, determining whether the first delta value exceeds a first threshold, administering a first intervention of level-0 if the first delta value does not exceed the first threshold, and administering a first intervention of level-N if the first delta value exceeds the first threshold, where N is an integer and N has a value of 1 or greater. In an aspect, the incidence of ulcers in patients in the care facility is reduced to less than 1 in 100, less than 1 in 200, less than 1 in 300, less than 1 in 400, less than 1 in 500, less than 1 in 600, less than 1 in 700, less than 1 in 800, less than 1 in 900, or less than 1 in 1000.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a barrier cream to the patient's heel, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's heel, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a barrier cream to the patient's heel if the delta value exceeds the threshold, and making a plurality of SEM measurements every two hours if the delta value exceeds the threshold. In an aspect, a plurality of SEM measurements are made at least once every hour or at least once every half an hour if the delta value exceeds the threshold.
In one aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a neuro-muscular stimulation to the patient's heel, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's heel, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a neuro-muscular stimulation to the patient's heel if the delta value exceeds the threshold, and making a plurality of SEM measurements every hour if the delta value exceeds the threshold. In an aspect, a plurality of SEM measurements are made at least once every half an hour if the delta value exceeds the threshold.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a topical cream to the patient's heel, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's heel, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a topical cream to the patient's heel if the delta value exceeds the threshold, and making a plurality of SEM measurements every half an hour if the delta value exceeds the threshold.
In one aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a barrier cream to the patient's sacrum, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's sacrum, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a barrier cream to the patient's sacrum if the delta value exceeds the threshold, and making a plurality of SEM measurements every six hours if the delta value exceeds the threshold. In an aspect, a plurality of SEM measurements are made at least once every four hours, at least once every three hours, at least once every two hours, at least once an hour, or at least once every half an hour if the delta value exceeds the threshold.
In an aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a neuro-muscular stimulation to the patient's sacrum, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's sacrum, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a neuro-muscular stimulation to the patient's sacrum if the delta value exceeds the threshold, and making a plurality of SEM measurements every four hours if the delta value exceeds the threshold. In an aspect, a plurality of SEM measurements are made at least once every three hours, at least once every two hours, at least once an hour, or at least once every half an hour if the delta value exceeds the threshold.
In one aspect, the present disclosure provides for, and includes, a method of identifying and treating a patient in need of application of a topical cream to the patient's sacrum, the method comprising the steps of: making a plurality of Sub-Epidermal Moisture (SEM) measurements at the patient's sacrum, calculating a delta value from a portion of the plurality of SEM measurements, determining whether the delta value exceeds a threshold corresponding to level N, where N is greater than or equal to 2, administering a topical cream to the patient's sacrum if the delta value exceeds the threshold, and making a plurality of SEM measurements every two hours if the delta value exceeds the threshold. In an aspect, a plurality of SEM measurements are made at least once an hour or at least once every half an hour if the delta value exceeds the threshold.
In an aspect, methods of the present disclosure are performed using the devices disclosed in U.S. application Ser. Nos. 14/827,375 and 15/134,110. In one aspect, the moisture content is equivalent to the SEM value on a predetermined scale. In an aspect, a predetermined scale may range from 0 to 20, such as from 0 to 1, from 0 to 2, from 0 to 3, from 0 to 4, from 0 to 5, from 0 to 6, from 0 to 7, from 0 to 8, from 0 to 9, from 0 to 10, from 0 to 11, from 0 to 12, from 0 to 13, from 0 to 14, from 0 to 15, from 0 to 16, from 0 to 17, from 0 to 18, from 0 to 19. In one aspect, a predetermined scale can be scaled by a factor or a multiple based on the values provided herein.
In an aspect, the present disclosure further provides for, and includes, providing targeted treatment to an anatomical location of a patient identified as being damaged by a combination of a visual assessment and SEM scan measurements. In one aspect, a targeted treatment is provided to a common site for pressure ulcers selected from the group consisting of: toes, heels, a sacrum, a spine, an elbows, shoulder blades, occiput, and ischial tuberosity. In an aspect, a targeted treatment is concurrently provided to a second common site for pressure ulcers selected from the group consisting of: toes, heels, a sacrum, a spine, an elbows, shoulder blades, occiput, and ischial tuberosity. In one aspect, a first site receiving a targeted treatment is known to cause a development of pressure ulcer at a second site.
The present disclosure is illustrated by the following examples. The examples set out herein illustrate several aspects of the present disclosure but should not be construed as limiting the scope of the present disclosure in any manner.
Subjects identified as being at risk for pressure ulcers in the heel were treated in accordance with the following scheme:
Subjects identified as being at risk for pressure ulcers in the sacrum were treated in accordance with the following scheme:
A patient was subjected to multiple SEM measurements at and around the boney prominence of the sacrum using an apparatus capable of measuring SEM measurements. Prior to performing the measurements, surface moisture and matter above the patient's skin surface were removed. An electrode of the apparatus was applied to the patient's skin with sufficient pressure to ensure complete contact for approximately one second to obtain each SEM measurement.
SEM measurements were taken on a straight line across the sacrum of a patient. Multiple measurements were taken at a given measurement location.
Additional SEM measurements were taken every 24 hours until discharge. There was no change in the intervention level.
A patient was subjected to multiple SEM measurements taken on a straight line across the sacrum in accordance with the same procedure as described in Example 3.
The calculated delta value was compared to a threshold value “T” in step 406. If the delta value was less than or equal to the threshold value, step 408 was executed and the caregiver waited until the monitoring interval associated with the current level of care transpires, then repeated the SEM measurements in step 402. If the delta value was greater than the threshold value, the amount by which the delta value exceeded the threshold value was compared to a cascading series of difference values.
In some instances, the delta value was positive and the comparison executed by subtracting the threshold value from the delta value, which produced a positive difference, and then a determination was made regarding whether the difference exceeded the first difference D1 in step 410. If the difference was less than D1, the process branched to step 412 and then step 414 to implement an intervention and measurement interval, respectively, associated with level-N+1. In this example, N had a value of zero or greater.
In some instances, the delta value was negative, for example if the SEM measurement at the center position of the data in
In some instances, the values of the new levels of intervention in the cells 506 were similar from row to row. In some instances, the values of the new levels of intervention in adjacent cells 506 differed by a single level or by more than one level. In some instances, the values of the new levels of intervention in adjacent cells 506 were the same in adjacent cells.
At time t2, the damage progressed and the delta value 676 was greater than the threshold 662, indicating that there was significant damage. This damage was still not visible on the skin. Nonetheless, a delta value greater than the threshold 662 indicated that there was cellular damage at a depth less than the sensitive depth of the SEM scanner.
At time t3, the damage continued but the amount of fluid in the intercellular space was decreased due to mechanical expulsion as illustrated in
At time t4, the damage progressed to the point where it was visible on the skin surface, as shown in
At time t5, the damage progressed to the point where sufficient fluid had been expelled from the local tissue that the SEM value of a measurement made over the damaged area was lower than the SEM value of healthy tissue. This resulted in the delta value 680 being negative, as shown in
This set of measurements enabled the creation of a map of a certain level of damage, for example the area 720. Repeating this mapping process at regular time intervals would provide an indication of whether the area 720 is growing, which may indicate that an increased level of intervention is appropriate, or shrinking, which may indicate that the current level of intervention is allowing the damage to heal.
Upon completion of the risk assessment, the patient is identified as (i) having a low risk of developing a pressure ulcer, (ii) being at risk of developing a pressure ulcer, or (iii) being at high risk of developing a pressure ulcer. Depending on the level of risk the patient is classified as having, the patient undergoes different sequences of treatment and evaluation by visual assessment.
All patients are potentially at risk of developing a pressure ulcer. They are more likely to occur in people who are seriously ill or have a neurological condition, impaired mobility, impaired nutrition, poor posture, or a deformity.
Pressure ulcers are categorized as stage-1 through stage-4, with stage-1 being the lowest condition. The National Pressure Ulcer Advisory Panel (NPUAP) has defined a “stage-1” ulcer as intact skin with a localized area of non-blanchable erythema, where “blanchable” indicates that the tissue loses all redness when pressed and “non-blanchable” tissue remains red when pressed due to the presence of red blood cells outside of blood vessels (extravasation). In some patients, blanchable erythema or changes in sensation, temperature, or firmness may precede visual changes.
Visual skin assessment (VSA) is the current method of identifying a pressure ulcer. A trained healthcare professional assesses the appearance of the skin, visually and tactilely, looking for redness or variations in tissue firmness, tissue temperature, or moisture.
If a patient is identified as having a low risk of developing a pressure ulcer, the patient is simply monitored for a change in clinical status such as undergoing surgery, worsening of an underlying condition, or a change in mobility. A patient who uses a wheelchair or sits for prolonged periods may be provided with a high-specification foam cushion or equivalent pressure-distributing cushion. If there is no change in clinical status, a low-risk patient will not be reassessed under this set of guidelines and stays within the same treatment and evaluation pathway until he or she is discharged from the care facility.
If a patient is identified as being at risk of developing a pressure ulcer, the patient will be scheduled to be turned, or “rounded,” every 6 hours. As with the low-risk patient, a high-spec foam cushion may be provided if the patient uses a wheelchair or sits for prolonged periods of time. No other monitoring or intervention is recommended by the NICE guidelines.
A high-risk patient receives a high-spec foam mattress as a preventative measure, provided with a high-spec cushion if they are in a wheelchair or sit for prolonged periods of time, and will be turned every 4 hours. The patient will receive a daily VSA for all areas of the body. If an area is found to have non-blanchable erythema, an appropriate intervention will be implemented and that area re-checked by VSA every 2 hours. Areas that do not exhibit non-blanchable erythema are re-checked daily by VSA. A personalized care plan will be developed for each high-risk patient.
It can be seen from this flow chart that the majority of the time spent by caregivers will be on the high-risk patients. While this may be appropriate, it leaves the at-risk patients unmonitored and they may develop a stage-1 ulcer before the condition is observed by a caregiver. Furthermore, the consequence of relying on VSA to detect a problem necessarily means that patients will develop a stage-1 ulcer before an intervention is selected or implemented. By the time that the damage has progressed to stage-1, it is likely that the skin will break and become a stage-2 ulcer despite intervention. There is a clear need to identify tissue damage earlier so that interventions can prevent progression of the subepidermal damage to stage-1 and beyond.
The augmented plan has the benefit of providing basic monitoring of all patients for pressure ulcers. The additional steps require additional time, however, either by adding staff or further burdening the existing staff. While superior to the recommended care pathway of
Various hospitals and care facilities use different numbers of risk categories, ranging from two categories, low-risk and at-risk, to four or more categories, adding categories such as “very-high-risk” to the categories of the example of
In an aspect, the clinician will perform an SEM scan of a body location identified as having possible damage in the initial SEM scan at a first time interval. The clinician will also perform an SEM scan of all other body locations selected for monitoring at a second time interval that is longer than the first time interval. In an aspect, the values of the first and second time intervals are different depending on the risk category to which the patient has been assigned. For example, a high-risk patient will have a first time interval of 4 hours and a second time interval of 1 day while an at-risk patient will have a first time interval of 1 day and a second time interval of 1 week. In an aspect, the time interval may be event-based, for example upon a change of attending staff or shift change, rather than strictly based on time. In general, body locations that have elevated delta values are scanned more often than other body locations that are monitored but having normal delta values in previous SEM scans.
In an aspect, the interval at which an SEM scan is performed is determined by the delta values from the prior SEM scan. For example, an SEM scan of a body location that had a delta value greater than or equal to a first threshold in a previous SEM scan is performed at a first time interval, while an SEM scan is performed at a second time interval that is shorter than the first time interval when the prior SEM scan of a body location had a delta value greater than or equal to a second threshold that is higher than the first threshold.
In this example, low-risk patients receive a weekly SEM scan of all body locations that are selected for monitoring. This is a small effort that provides basic protection for even the healthiest patients, as a weekly SEM scan is likely to detect tissue damage before it becomes visible to VSA.
At-risk patients, which will include patients that would be identified as high-risk in the current care pathways of
A decision whether to implement an intervention, for example turning the patient at a first interval, is currently based on the VSA and risk assessment despite the uncertainty of whether there is early stage damage below the skin. In an aspect, the decision to implement an intervention for a particular body site, or a general intervention such as a high-spec mattress, is based on the delta value found for that site in the SEM scan. If the delta value is less than a predetermined threshold, no intervention is required. If the delta value is greater than the predetermined threshold, then an intervention is selected and implemented based partially on the body location and partially on the delta value for that body location. The predetermined threshold for whether or not to select and implement an intervention may be higher or lower than the threshold for determination that there is possible damage at the body location.
A comparison of the costs of provided the care pathways of
The baseline for this comparison is the augmented current practice of
Integrating the SEM scanner into the current “best practice” workflow, as shown in
In an aspect, a central “registry” or database 1160 is established to aggregate data from all care settings as well as the condition of the patient at the time of transfer between care settings.
While in each care setting, for example the home care setting 1120, health information regarding the patient is recorded and transferred to the database 1160 in a data record 1112. The health information may include the results of examinations or tests, observations, measurements, treatments, the implementation of interventions that are intended to prevent the development of pressure ulcers, dietary notations, and other records related to the condition and treatment of the patient. A data record from a care setting may include one or more of a patient identifier, a data element from the group of nutritional information, an implemented intervention, a risk assessment, a visual skin assessment, a care plan, a doctor's note, lean event, a vital sign, a “measure of health” such as skin redness or an indication of mobility or a measure of cognition, a body weight, and a lab result, and a date/time associated with the data element. Data records may vary in structure and content. A data record reported to the database may contain one of more of the following data elements:
When a patient is transferred between care setting, for example from the home care setting 1110 to the med/surg care setting 1120, a transfer record 1114 is created and reported to the database 1160. Transferring information regarding risk and health information related to pressure ulcers will improve the care provided in the new care setting. In an aspect, the transfer record 1114 comprises a patient assessment performed at the “from” care site after the decision to transfer the patient has been made. In an aspect, the assessment comprises an SEM scan of at least one body location, wherein the SEM scan comprises a plurality of SEM values measured at a single body location and calculation of a delta value from the plurality of SEM values. In an aspect, the transfer record contains a history of prior SEM values and/or delta values while in the “from” care setting. In an aspect, the transfer record contains one or more of a VSA, a risk analysis, and other health data. A transfer record may contain one of more of the following data elements:
A patient may move periodically from a primary care setting, for example a home care setting 1110, to an advanced care setting, for example a long-term acute care unit 1130, where the patient will undergo an “episode of care” by doctors or other skilled professionals. Data records of the assessments and care provided in the advanced care setting are reported to the database 1160. Upon discharge from the long-term acute care setting 1130 to the home setting 1110, data records containing care instructions, prescriptions, and other guidance for care in the home setting 1110.
With data from the entire care pathway 1100 aggregated in the database 1160, it is possible to query the database 1160 to retrieve the delta values observed over time for a particular patient across multiple care settings and various episodes of care.
In an aspect, a query is structured to determine whether instructions from monitoring and/or treatment of a patient are being followed.
In an aspect, a query is structured to determine whether a treatment of a patient is effective.
In an aspect, a query is structured to determine whether an outcome of a patient is related to one or more of the data elements reported to the database 1160.
In an aspect, a query is structured to retrieve one or more measures of health along with delta values to evaluate possible linkages between the retrieved measures of health and the development of a pressure ulcer or other outcomes (development of other health con. The delta values are plotted against the date/time of measurement to form a time history of the delta values for a body location. In an aspect, the dealt values are analyzed to determine one or more of a slope, an acceleration, a curve shape and associated characteristics, and a time-to-intercept of a selected threshold value. In an aspect, these analytical results can be used to implement the methods and processes of
From the foregoing, it will be appreciated that the present disclosure can be embodied in various ways, which include but are not limited to the following:
While the present disclosure has been described with reference to particular aspects, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the disclosure. In addition, many modifications may be made to a particular situation or material to the teachings of the disclosure without departing from the scope of the disclosure. Therefore, it is intended that the disclosure not be limited to the particular aspects disclosed but that the disclosure will include all aspects falling within the scope and spirit of the appended claims.
This application is a continuation of U.S. Non-Provisional application Ser. No. 16/193,707 filed Nov. 16, 2018, which claims benefit of U.S. Provisional Application No. 62/587,337, which was filed Nov. 16, 2017 and U.S. Provisional Application No. 62/693,810, which was filed Jul. 3, 2018. The entire content of these applications is incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3851641 | Toole et al. | Dec 1974 | A |
| 4295009 | Weidler | Oct 1981 | A |
| 4557271 | Stoller et al. | Dec 1985 | A |
| 4857716 | Gombrich et al. | Aug 1989 | A |
| 4860753 | Amerena | Aug 1989 | A |
| 5001436 | Scot | Mar 1991 | A |
| 5073126 | Kikuchi et al. | Dec 1991 | A |
| 5152296 | Simons | Oct 1992 | A |
| 5284150 | Butterfield et al. | Feb 1994 | A |
| 5292341 | Snell | Mar 1994 | A |
| 5367789 | Lamont | Nov 1994 | A |
| 5815416 | Liebmann et al. | Sep 1998 | A |
| 5904581 | Pope et al. | May 1999 | A |
| 6185452 | Schulman | Feb 2001 | B1 |
| 6204749 | Ishihara | Mar 2001 | B1 |
| 6223088 | Scharnberg et al. | Apr 2001 | B1 |
| 6254435 | Cheong et al. | Jul 2001 | B1 |
| 6312263 | Higuchi et al. | Nov 2001 | B1 |
| 6330479 | Stauffer | Dec 2001 | B1 |
| 6368284 | Bardy | Apr 2002 | B1 |
| 6370426 | Campbell et al. | Apr 2002 | B1 |
| 6434422 | Tomoda et al. | Aug 2002 | B1 |
| 6577700 | Fan et al. | Jun 2003 | B1 |
| 6634045 | DuDonis | Oct 2003 | B1 |
| 6738798 | Ploetz | May 2004 | B1 |
| 6756793 | Hirono | Jun 2004 | B2 |
| 6963772 | Bloom et al. | Nov 2005 | B2 |
| 7079899 | Petrofsky | Jul 2006 | B2 |
| 7291023 | Still et al. | Nov 2007 | B1 |
| 7315767 | Caduff et al. | Jan 2008 | B2 |
| 7402135 | Leveque et al. | Jul 2008 | B2 |
| 7783344 | Lackey et al. | Aug 2010 | B2 |
| 8011041 | Hann | Sep 2011 | B2 |
| 8060315 | Brosette et al. | Nov 2011 | B2 |
| 8355925 | Rothman | Jan 2013 | B2 |
| 8390583 | Forutanpour et al. | Mar 2013 | B2 |
| 8494617 | Baker, Jr. et al. | Jul 2013 | B2 |
| 8648707 | Franz et al. | Feb 2014 | B2 |
| 8690785 | Lading | Apr 2014 | B2 |
| 8724833 | Shain et al. | May 2014 | B1 |
| 8925392 | Esposito et al. | Jan 2015 | B2 |
| 9028407 | Bennett-Guerrero | May 2015 | B1 |
| 9095305 | Engler et al. | Aug 2015 | B2 |
| 9220455 | Sarrafzadeh et al. | Dec 2015 | B2 |
| 9271676 | Alanen et al. | Mar 2016 | B2 |
| 9398879 | Sarrafzadeh et al. | Jul 2016 | B2 |
| 9675289 | Heaton | Jun 2017 | B2 |
| 9763596 | Tonar et al. | Sep 2017 | B2 |
| 9949683 | Afentakis | Apr 2018 | B2 |
| 9980673 | Sarrafzadeh et al. | May 2018 | B2 |
| 10085643 | Bandic et al. | Oct 2018 | B2 |
| 10126340 | Simmons | Nov 2018 | B2 |
| 10166387 | Bergelin et al. | Jan 2019 | B2 |
| 10178961 | Tonar et al. | Jan 2019 | B2 |
| 10182740 | Tonar et al. | Jan 2019 | B2 |
| 10188340 | Sarrafzadeh et al. | Jan 2019 | B2 |
| 10194856 | Afentakis et al. | Feb 2019 | B2 |
| 10206604 | Bergelin et al. | Feb 2019 | B2 |
| 10226187 | Al-Ali et al. | Mar 2019 | B2 |
| 10278636 | Wu et al. | May 2019 | B2 |
| 10285898 | Douglas et al. | May 2019 | B2 |
| 10307060 | Tran | Jun 2019 | B2 |
| 10342482 | Lisy et al. | Jul 2019 | B1 |
| 10383527 | Al-Ali | Aug 2019 | B2 |
| 10420602 | Horton et al. | Sep 2019 | B2 |
| 10441185 | Rogers et al. | Oct 2019 | B2 |
| 10448844 | Al-Ali et al. | Oct 2019 | B2 |
| 10463293 | Maharbiz et al. | Nov 2019 | B2 |
| 10485447 | Tonar et al. | Nov 2019 | B2 |
| 10898129 | Burns et al. | Jan 2021 | B2 |
| 10950960 | Burns et al. | Mar 2021 | B2 |
| 10959664 | Burns et al. | Mar 2021 | B2 |
| 11172871 | Bly et al. | Nov 2021 | B2 |
| 11191477 | Burns | Dec 2021 | B2 |
| 11253192 | Sarrafzadeh et al. | Feb 2022 | B2 |
| 11284810 | Tonar et al. | Mar 2022 | B2 |
| 11304652 | Burns et al. | Apr 2022 | B2 |
| 11337651 | Burns et al. | May 2022 | B2 |
| 11342696 | Burns et al. | May 2022 | B2 |
| 11426118 | Burns | Aug 2022 | B2 |
| 11471094 | Burns et al. | Oct 2022 | B2 |
| 11534077 | Tonar et al. | Dec 2022 | B2 |
| 11600939 | Burns et al. | Mar 2023 | B2 |
| 11627910 | Burns et al. | Apr 2023 | B2 |
| 11642075 | Burns et al. | May 2023 | B2 |
| 11779265 | Sarrafzadeh et al. | Oct 2023 | B2 |
| 11824291 | Burns et al. | Nov 2023 | B2 |
| 11832929 | Tonar et al. | Dec 2023 | B2 |
| 11980475 | Burns et al. | May 2024 | B2 |
| 12097041 | Burns et al. | Sep 2024 | B2 |
| 12132271 | Burns et al. | Oct 2024 | B2 |
| 20010049609 | Girouard et al. | Dec 2001 | A1 |
| 20010051783 | Edwards et al. | Dec 2001 | A1 |
| 20020016535 | Martin et al. | Feb 2002 | A1 |
| 20020032485 | Flam et al. | Mar 2002 | A1 |
| 20020070866 | Newham | Jun 2002 | A1 |
| 20020112898 | Honda et al. | Aug 2002 | A1 |
| 20020143262 | Bardy | Oct 2002 | A1 |
| 20030009244 | Engleson et al. | Jan 2003 | A1 |
| 20030036674 | Bouton | Feb 2003 | A1 |
| 20030036713 | Bouton et al. | Feb 2003 | A1 |
| 20030110662 | Gilman et al. | Jun 2003 | A1 |
| 20030116447 | Surridge et al. | Jun 2003 | A1 |
| 20030130427 | Cleary et al. | Jul 2003 | A1 |
| 20030139255 | Lina | Jul 2003 | A1 |
| 20030199783 | Bloom et al. | Oct 2003 | A1 |
| 20040041029 | Postman et al. | Mar 2004 | A1 |
| 20040046668 | Smith et al. | Mar 2004 | A1 |
| 20040054298 | Masuo et al. | Mar 2004 | A1 |
| 20040080325 | Ogura | Apr 2004 | A1 |
| 20040133092 | Kain | Jul 2004 | A1 |
| 20040147977 | Petrofsky | Jul 2004 | A1 |
| 20040171962 | Leveque et al. | Sep 2004 | A1 |
| 20040176754 | Island et al. | Sep 2004 | A1 |
| 20040236200 | Say et al. | Nov 2004 | A1 |
| 20040254457 | Van Der Weide | Dec 2004 | A1 |
| 20050027175 | Yang | Feb 2005 | A1 |
| 20050049658 | Connors et al. | Mar 2005 | A1 |
| 20050070778 | Lackey et al. | Mar 2005 | A1 |
| 20050086072 | Fox, Jr. et al. | Apr 2005 | A1 |
| 20050096513 | Ozguz et al. | May 2005 | A1 |
| 20050177061 | Alanen et al. | Aug 2005 | A1 |
| 20050203435 | Nakada | Sep 2005 | A1 |
| 20050215918 | Frantz et al. | Sep 2005 | A1 |
| 20050245795 | Goode et al. | Nov 2005 | A1 |
| 20050251418 | Fox, Jr. et al. | Nov 2005 | A1 |
| 20060052678 | Drinan et al. | Mar 2006 | A1 |
| 20060058593 | Drinan et al. | Mar 2006 | A1 |
| 20060097949 | Luebke et al. | May 2006 | A1 |
| 20060206013 | Rothman et al. | Sep 2006 | A1 |
| 20060239547 | Robinson et al. | Oct 2006 | A1 |
| 20070043282 | Mannheimer et al. | Feb 2007 | A1 |
| 20070051362 | Sullivan et al. | Mar 2007 | A1 |
| 20070106172 | Abreu | May 2007 | A1 |
| 20070179585 | Chandler et al. | Aug 2007 | A1 |
| 20070185392 | Sherman et al. | Aug 2007 | A1 |
| 20070191273 | Ambati et al. | Aug 2007 | A1 |
| 20070213700 | Davison et al. | Sep 2007 | A1 |
| 20070248542 | Kane et al. | Oct 2007 | A1 |
| 20080009764 | Davies | Jan 2008 | A1 |
| 20080015894 | Miller | Jan 2008 | A1 |
| 20080027509 | Andino et al. | Jan 2008 | A1 |
| 20080039700 | Drinan et al. | Feb 2008 | A1 |
| 20080048680 | Hargreaves et al. | Feb 2008 | A1 |
| 20080054276 | Vogel et al. | Mar 2008 | A1 |
| 20080063363 | Kientz et al. | Mar 2008 | A1 |
| 20080166268 | Yamaguchi et al. | Jul 2008 | A1 |
| 20080259577 | Hu et al. | Oct 2008 | A1 |
| 20080278336 | Ortega et al. | Nov 2008 | A1 |
| 20090047694 | Shuber | Feb 2009 | A1 |
| 20090054752 | Jonnalagadda et al. | Feb 2009 | A1 |
| 20090076410 | Libbus et al. | Mar 2009 | A1 |
| 20090104797 | Tseng et al. | Apr 2009 | A1 |
| 20090124924 | Eror et al. | May 2009 | A1 |
| 20090189092 | Aoi et al. | Jul 2009 | A1 |
| 20090209830 | Nagle et al. | Aug 2009 | A1 |
| 20090285785 | Jimi et al. | Nov 2009 | A1 |
| 20090306487 | Crowe et al. | Dec 2009 | A1 |
| 20090326346 | Kracker et al. | Dec 2009 | A1 |
| 20100017182 | Voros et al. | Jan 2010 | A1 |
| 20100030167 | Thirstrup et al. | Feb 2010 | A1 |
| 20100042389 | Farruggia et al. | Feb 2010 | A1 |
| 20100073170 | Siejko et al. | Mar 2010 | A1 |
| 20100113979 | Sarrafzadeh et al. | May 2010 | A1 |
| 20100152551 | Hsu et al. | Jun 2010 | A1 |
| 20100268111 | Drinan et al. | Oct 2010 | A1 |
| 20100298687 | Yoo et al. | Nov 2010 | A1 |
| 20100312076 | Bly et al. | Dec 2010 | A1 |
| 20100312233 | Furnish et al. | Dec 2010 | A1 |
| 20100324455 | Rangel et al. | Dec 2010 | A1 |
| 20100324611 | Deming et al. | Dec 2010 | A1 |
| 20110015697 | McAdams | Jan 2011 | A1 |
| 20110046505 | Cornish et al. | Feb 2011 | A1 |
| 20110160548 | Forster | Jun 2011 | A1 |
| 20110175844 | Berggren | Jul 2011 | A1 |
| 20110184264 | Galasso et al. | Jul 2011 | A1 |
| 20110191122 | Kharraz Tavakol | Aug 2011 | A1 |
| 20110223078 | Ohashi | Sep 2011 | A1 |
| 20110237926 | Jensen | Sep 2011 | A1 |
| 20110263950 | Larson et al. | Oct 2011 | A1 |
| 20110301441 | Bandic et al. | Dec 2011 | A1 |
| 20110313311 | Gaw | Dec 2011 | A1 |
| 20120029410 | Koenig et al. | Feb 2012 | A1 |
| 20120061257 | Yu et al. | Mar 2012 | A1 |
| 20120078088 | Whitestone et al. | Mar 2012 | A1 |
| 20120083672 | Cui et al. | Apr 2012 | A1 |
| 20120150011 | Besio | Jun 2012 | A1 |
| 20120179006 | Jansen et al. | Jul 2012 | A1 |
| 20120190989 | Kaiser et al. | Jul 2012 | A1 |
| 20120271121 | Della Torre et al. | Oct 2012 | A1 |
| 20130041235 | Rogers et al. | Feb 2013 | A1 |
| 20130072870 | Heppe et al. | Mar 2013 | A1 |
| 20130121544 | Sarrafzadeh et al. | May 2013 | A1 |
| 20130123587 | Sarrafzadeh et al. | May 2013 | A1 |
| 20130137951 | Chuang et al. | May 2013 | A1 |
| 20130253285 | Bly et al. | Sep 2013 | A1 |
| 20130261496 | Engler et al. | Oct 2013 | A1 |
| 20130301255 | Kim et al. | Nov 2013 | A1 |
| 20130310440 | Duskin et al. | Nov 2013 | A1 |
| 20130333094 | Rogers et al. | Dec 2013 | A1 |
| 20130338661 | Behnke, II | Dec 2013 | A1 |
| 20140121479 | O'Connor et al. | May 2014 | A1 |
| 20140142984 | Wright et al. | May 2014 | A1 |
| 20140288397 | Sarrafzadeh et al. | Jun 2014 | A1 |
| 20140200486 | Bechtel et al. | Jul 2014 | A1 |
| 20140221792 | Miller et al. | Aug 2014 | A1 |
| 20140273025 | Hurskainen et al. | Sep 2014 | A1 |
| 20140275823 | Lane et al. | Sep 2014 | A1 |
| 20140298928 | Duesterhoft | Oct 2014 | A1 |
| 20140316297 | McCaughan et al. | Oct 2014 | A1 |
| 20140318699 | Longinotti-Buitoni et al. | Oct 2014 | A1 |
| 20140365241 | Dillie et al. | Dec 2014 | A1 |
| 20150002168 | Kao et al. | Jan 2015 | A1 |
| 20150009168 | Levesque et al. | Jan 2015 | A1 |
| 20150094548 | Sabatini et al. | Apr 2015 | A1 |
| 20150157435 | Chasins et al. | Jun 2015 | A1 |
| 20150186607 | Geleijnse | Jul 2015 | A1 |
| 20150230863 | Youngquist et al. | Aug 2015 | A1 |
| 20150343173 | Tobescu et al. | Dec 2015 | A1 |
| 20150363567 | Pettus | Dec 2015 | A1 |
| 20150366499 | Sarrafzadeh et al. | Dec 2015 | A1 |
| 20150371522 | Mravyan et al. | Dec 2015 | A1 |
| 20160015962 | Shokoueinejad Maragheh et al. | Jan 2016 | A1 |
| 20160038055 | Wheeler et al. | Feb 2016 | A1 |
| 20160058342 | Maiz-Aguinaga et al. | Mar 2016 | A1 |
| 20160072308 | Nyberg et al. | Mar 2016 | A1 |
| 20160081580 | Bergelin et al. | Mar 2016 | A1 |
| 20160100790 | Cantu et al. | Apr 2016 | A1 |
| 20160101282 | Bergelin et al. | Apr 2016 | A1 |
| 20160166438 | Rovaniemi | Jun 2016 | A1 |
| 20160174631 | Tong et al. | Jun 2016 | A1 |
| 20160174871 | Sarrafzadeh et al. | Jun 2016 | A1 |
| 20160220172 | Sarrafzadeh et al. | Aug 2016 | A1 |
| 20160270672 | Chen et al. | Sep 2016 | A1 |
| 20160270968 | Stanford et al. | Sep 2016 | A1 |
| 20160278692 | Larson | Sep 2016 | A1 |
| 20160296268 | Gee et al. | Oct 2016 | A1 |
| 20160310034 | Tonar | Oct 2016 | A1 |
| 20160338591 | Lachenbruch | Nov 2016 | A1 |
| 20160374588 | Shariff | Dec 2016 | A1 |
| 20170007153 | Tonar | Jan 2017 | A1 |
| 20170014044 | Tonar et al. | Jan 2017 | A1 |
| 20170014045 | Tonar et al. | Jan 2017 | A1 |
| 20170105646 | Bryenton et al. | Apr 2017 | A1 |
| 20170124279 | Rothman | May 2017 | A1 |
| 20170156658 | Maharbiz et al. | Jun 2017 | A1 |
| 20170172489 | Afentakis | Jun 2017 | A1 |
| 20170188841 | Ma et al. | Jul 2017 | A1 |
| 20170238849 | Chapman et al. | Aug 2017 | A1 |
| 20170245799 | Fleischer et al. | Aug 2017 | A1 |
| 20170255812 | Kwon | Sep 2017 | A1 |
| 20170311807 | Fu et al. | Nov 2017 | A1 |
| 20170319066 | Ver Steeg | Nov 2017 | A1 |
| 20170319073 | DiMaio et al. | Nov 2017 | A1 |
| 20180020058 | Martines et al. | Jan 2018 | A1 |
| 20180045725 | Yoo et al. | Feb 2018 | A1 |
| 20180220924 | Burns et al. | Aug 2018 | A1 |
| 20180220953 | Burns et al. | Aug 2018 | A1 |
| 20180220954 | Burns et al. | Aug 2018 | A1 |
| 20180220961 | Burns et al. | Aug 2018 | A1 |
| 20180360344 | Burns et al. | Dec 2018 | A1 |
| 20190000352 | Everett et al. | Jan 2019 | A1 |
| 20190038133 | Tran | Feb 2019 | A1 |
| 20190053751 | Torres | Feb 2019 | A1 |
| 20190060602 | Tran et al. | Feb 2019 | A1 |
| 20190069836 | Hettrick | Mar 2019 | A1 |
| 20190104981 | Sarrafzadeh et al. | Apr 2019 | A1 |
| 20190104982 | Dunn et al. | Apr 2019 | A1 |
| 20190117964 | Bahrami et al. | Apr 2019 | A1 |
| 20190134396 | Toth et al. | May 2019 | A1 |
| 20190142333 | Burns et al. | May 2019 | A1 |
| 20190147990 | Burns et al. | May 2019 | A1 |
| 20190148901 | Komoto | May 2019 | A1 |
| 20190150882 | Maharbiz et al. | May 2019 | A1 |
| 20190175098 | Burns et al. | Jun 2019 | A1 |
| 20190192066 | Schoess et al. | Jun 2019 | A1 |
| 20190246972 | Burns et al. | Aug 2019 | A1 |
| 20190282436 | Douglas et al. | Sep 2019 | A1 |
| 20190290189 | Sarrafzadeh et al. | Sep 2019 | A1 |
| 20190307360 | Tonar et al. | Oct 2019 | A1 |
| 20190307405 | Terry et al. | Oct 2019 | A1 |
| 20200008299 | Tran et al. | Jan 2020 | A1 |
| 20200043607 | Zerhusen et al. | Feb 2020 | A1 |
| 20200069240 | Burns | Mar 2020 | A1 |
| 20200069242 | Burns et al. | Mar 2020 | A1 |
| 20200077892 | Tran | Mar 2020 | A1 |
| 20200078499 | Gadde et al. | Mar 2020 | A1 |
| 20200093395 | Tonar et al. | Mar 2020 | A1 |
| 20200100723 | Burns | Apr 2020 | A1 |
| 20200113488 | Al-Ali et al. | Apr 2020 | A1 |
| 20200127398 | Burns et al. | Apr 2020 | A1 |
| 20200296821 | Trublowski et al. | Sep 2020 | A1 |
| 20200297244 | Brownhill et al. | Sep 2020 | A1 |
| 20200297255 | Martinez et al. | Sep 2020 | A1 |
| 20210076974 | Burns | Mar 2021 | A1 |
| 20210159621 | Burns et al. | May 2021 | A1 |
| 20210204864 | Burns et al. | Jul 2021 | A1 |
| 20210307635 | Burns | Oct 2021 | A1 |
| 20220071555 | Burns et al. | Mar 2022 | A1 |
| 20220192587 | Burns et al. | Jun 2022 | A1 |
| 20220211291 | Tonar et al. | Jul 2022 | A1 |
| 20220240840 | Burns | Aug 2022 | A1 |
| 20220273238 | Burns et al. | Sep 2022 | A1 |
| 20220285865 | Burns et al. | Sep 2022 | A1 |
| 20220287584 | Burns et al. | Sep 2022 | A1 |
| 20220330847 | Burns et al. | Oct 2022 | A1 |
| 20220409086 | Burns | Dec 2022 | A1 |
| 20230068683 | Burns et al. | Mar 2023 | A1 |
| 20230109698 | Tonar et al. | Apr 2023 | A1 |
| 20230148893 | Burns et al. | May 2023 | A1 |
| 20230363698 | Burns | May 2023 | A9 |
| 20230337966 | Sarrafzadeh et al. | Jun 2023 | A1 |
| 20230240592 | Burns et al. | Aug 2023 | A1 |
| 20230329629 | Burns et al. | Oct 2023 | A1 |
| 20230335929 | Burns et al. | Oct 2023 | A1 |
| 20230346240 | Tonar et al. | Nov 2023 | A1 |
| 20240039192 | Burns et al. | Feb 2024 | A1 |
| 20240081727 | Burns | Mar 2024 | A1 |
| 20240138696 | Burns et al. | May 2024 | A1 |
| 20240225529 | Burns | Jul 2024 | A1 |
| 20240268753 | Burns et al. | Aug 2024 | A1 |
| 20240389932 | Burns et al. | Nov 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 2020103438 | Jan 2021 | AU |
| 2811609 | Nov 2011 | CA |
| 2609842 | Oct 2016 | CA |
| 102033166 | Apr 2011 | CN |
| 204119175 | Jan 2015 | CN |
| 104352230 | Feb 2015 | CN |
| 104567657 | Apr 2015 | CN |
| 104644125 | May 2015 | CN |
| 105578333 | May 2016 | CN |
| 105963074 | Sep 2016 | CN |
| 208111467 | Nov 2018 | CN |
| 102012011212 | Jan 2012 | DE |
| 0970656 | Jan 2000 | EP |
| 1080687 | Mar 2001 | EP |
| 1372475 | Jan 2004 | EP |
| 1569553 | Sep 2005 | EP |
| 3092946 | Nov 2016 | EP |
| 3280488 | Dec 2018 | EP |
| 2148513 | May 1985 | GB |
| 2584808 | Dec 2020 | GB |
| H06-502323 | Mar 1994 | JP |
| H10-201726 | Aug 1998 | JP |
| 2000-060805 | Feb 2000 | JP |
| 2001-178705 | Jul 2001 | JP |
| 2001-326773 | Nov 2001 | JP |
| 2003-169787 | Jun 2003 | JP |
| 2003-169788 | Jun 2003 | JP |
| 2003-202312 | Jul 2003 | JP |
| 2003-290166 | Oct 2003 | JP |
| 2005-52227 | Mar 2005 | JP |
| 2009-268611 | Nov 2009 | JP |
| 4418419 | Feb 2010 | JP |
| 2013-528428 | Jul 2013 | JP |
| 2013-198639 | Oct 2013 | JP |
| 2015-509028 | Mar 2015 | JP |
| 2015-134074 | Jul 2015 | JP |
| 2016-519969 | Jul 2016 | JP |
| 2016-527943 | Sep 2016 | JP |
| 10-2014-0058445 | May 2014 | KR |
| 9610951 | Apr 1996 | WO |
| 2001054580 | Aug 2001 | WO |
| 2002080770 | Oct 2002 | WO |
| 2004105602 | Dec 2004 | WO |
| 2005099644 | Oct 2005 | WO |
| 2006029035 | Mar 2006 | WO |
| 2007098762 | Sep 2007 | WO |
| 2009144615 | Dec 2009 | WO |
| 2010060102 | May 2010 | WO |
| 2011004165 | Jan 2011 | WO |
| 2011022418 | Feb 2011 | WO |
| 2011048556 | Apr 2011 | WO |
| 2011080080 | Jul 2011 | WO |
| 2011080262 | Jul 2011 | WO |
| 2011084722 | Jul 2011 | WO |
| 2011091517 | Aug 2011 | WO |
| 2011143071 | Nov 2011 | WO |
| 2013033724 | Mar 2013 | WO |
| 2013114356 | Aug 2013 | WO |
| 2013116242 | Aug 2013 | WO |
| 2013140714 | Sep 2013 | WO |
| 2014186894 | Nov 2014 | WO |
| 2015003015 | Jan 2015 | WO |
| 2015022583 | Feb 2015 | WO |
| 2015077838 | Jun 2015 | WO |
| 2015168720 | Nov 2015 | WO |
| 2015169911 | Nov 2015 | WO |
| 2015195720 | Dec 2015 | WO |
| 2016098062 | Jun 2016 | WO |
| 2016172263 | Oct 2016 | WO |
| 2016172264 | Oct 2016 | WO |
| 2017032393 | Mar 2017 | WO |
| 2017214188 | Dec 2017 | WO |
| 2017218818 | Dec 2017 | WO |
| 2018071715 | Apr 2018 | WO |
| 2018077560 | May 2018 | WO |
| 2018115461 | Jun 2018 | WO |
| 2018144938 | Aug 2018 | WO |
| 2018144941 | Aug 2018 | WO |
| 2018144943 | Aug 2018 | WO |
| 2018144946 | Aug 2018 | WO |
| 2018168424 | Sep 2018 | WO |
| 2018189265 | Oct 2018 | WO |
| 2018209100 | Nov 2018 | WO |
| 2018234443 | Dec 2018 | WO |
| 2018236739 | Dec 2018 | WO |
| 2019020551 | Jan 2019 | WO |
| 2019030384 | Feb 2019 | WO |
| 2019048624 | Mar 2019 | WO |
| 2019048626 | Mar 2019 | WO |
| 2019048638 | Mar 2019 | WO |
| 2019072531 | Apr 2019 | WO |
| 2019073389 | Apr 2019 | WO |
| 2019076967 | Apr 2019 | WO |
| 2019096828 | May 2019 | WO |
| 2019099810 | May 2019 | WO |
| 2019099812 | May 2019 | WO |
| 2019113481 | Jun 2019 | WO |
| 2019157290 | Aug 2019 | WO |
| 2019162272 | Aug 2019 | WO |
| 2020014779 | Jan 2020 | WO |
| 2020043806 | Mar 2020 | WO |
| 2020053290 | Mar 2020 | WO |
| 2020077100 | Apr 2020 | WO |
| 2020187643 | Sep 2020 | WO |
| 2020187851 | Sep 2020 | WO |
| 2020234429 | Nov 2020 | WO |
| Entry |
|---|
| Christine Berggren, “Electroanalysis—Capacitive Biosensors”, 2001, 13, No. 3, pp. 173-180 (Year: 2001). |
| Brem et al., “Protocol for the successful treatment of pressure ulcers”, Jul. 2004, pp. 9S-17S (Year: 2004). |
| Liu, “A systematic review of electrical stimulation for pressure ulcer prevention and treatment in people with spinal cord injuries”, 2014, pp. 703-718 (Year: 2014). |
| Rotaru, “Friction between human skin and medical textiles for decubitus prevention”, 2013, pp. 91-96 (Year: 2013). |
| Thomas, “Prevention and Treatment of Pressure Ulcers”, 2006, pp. 46-59 (Year: 2006). |
| Truong, “Pressure Ulcer Prevention in the Hospital Setting Using Silicone Foam Dressings”, 2016, pp. 1-6 (Year: 2016). |
| Tur, “Topical hydrogen peroxide treatment of ischemic ulcers in the guinea pig: Blood recruitment in multiple skin sites”, 1995, pp. 217-221 (Year: 1995). |
| Alanen, “Measurement of Hydration in the Stratum Corneum with the MoistureMeter and Comparison with the Corneometer,” Skin Research and Technology, 10:32-37 (2004), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Alberts et al., “The Extracellular Matrix of Animals,” Molecular Biology of the Cell, 4th ed., pp. 1065-1127 (2002), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Allman et al., “Pressure Ulcer Risk Factors Among Hospitalized Patients with Activity Limitation,” JAMA, 273:865-870 (1995), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Anonymous, “Recommended Practices for Positioning the Patient in the Perioperative Practice Setting,” in Perioperative Standards, Recommended Practices, and Guidelines, AORN, Inc., 525-548 (2006), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Arao et al., “Morphological Characteristics of the Dermal Papillae In the Development of Pressure Sores,” World Wide Wounds, (1999), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Australian Intellectual Property Office, Office Action issued on May 1, 2014 for corresponding Australian patent application No. 2011253253 (pp. 1-10) and pending claims (pp. 11-15) pp. 1-15, Submitted in parent application U.S. Appl. No. 16/193,707. |
| Australian Patent Office, Office Action issued on Jun. 1, 2015, for corresponding Australian Patent Application No. 2011253253 (pp. 1-4) and claims (pp. 5-10) pp. 1-10, Submitted in parent application U.S. Appl. No. 16/193,707. |
| Bader et al., “Effect of Externally Applied Skin Surface Forces on Tissue Vasculature,” Archives of Physical Medicine and Rehabilitation, 67(11):807-11 (1986), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Barnes, “Moisture Meters for Use on Thin Lumber and Veneers,” Moisture Register Co., 1-5 (1956), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Bates-Jensen et al., “Subepidermal Moisture Predicts Erythema and Stage 1 Pressure Ulcers in Nursing Home Residents: A Pilot Study,” Journal of the American Geriatric Society, 55:1199-1205 (2007), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Bates-Jensen et al., “Subepidermal moisture differentiates erythema and stage 1 pressure ulcers in nursing home residents,” Wound Repair Regeneration, 16:189-197 (2008), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Bates-Jensen et al., “Subepidermal Moisture Is Associated With Early Pressure Ulcer Damage in Nursing Home Residents With Dark Skin Tones; Pilot Findings,” Journal of Wound Ostomy and Continence Nursing, 36(3):277-284 (2009), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Bergstrand et al., “Pressure-induced Vasodilation and Reactive Hyperemia at Different Depths in Sacral Tissue Under Clinically Relevant Conditions,” Microcirculation, 21:761-771 (2014), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Bergstrom et al., “Pressure Ulcers in Adults: Prediction and Prevention,” Clinical Practice Guideline—Quick Reference Guide for Clinicians, 117 (1992), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Brem et al., “High cost of stage IV pressure ulcers,” American Journal of Surgery, 200:473-477 (2010), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Brienza et al., “Friction-Induced Skin Injuries—Are They Pressure Ulcers?,” Journal of Wound Ostomy and Continence Nursing, 42(1):62-64 (2015), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Carmo-Araujo et al., “Ischaemia and reperfusion effects on skeletal muscle tissue: morphological and histochemical studies,” International Journal of Experimental Pathology, 88:147-154 (2007), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Ceelen et al., “Compression-induced damage and internal tissue strains are related,” Journal of Biomechanics, 41:3399-3404 (2008), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Ching et al., “Tissue electrical properties monitoring for the prevention of pressure sore” Prosthetics and Orthotics International, 35(4):386-394 (2011), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Clendenin et al., “Inter-operator and inter-device agreement and reliability of the SEM Scanner,” Journal of Tissue Viability, 24(1):17-23 (2015), Submitted in parent application U.S. Appl. No. 16/193,707. |
| De Lorenzo et al., “Predicting body cell mass with bioimpedance by using theoretical methods: a technological review,” Journal of Applied Physiology, 82(5):1542-1558 (1997), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Demarre et al., “The cost of pressure ulcer prevention and treatment in hospitals and nursing homes in Flanders: A cost-of-illness study,” International Journal of Nursing Studies, 1-14 (2015), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Dodde et al., “Bioimpedance of soft tissue under compression,” Physiology Measurement, 33(6):1095-1109 (2012), Submitted in parent application U.S. Appl. No. 16/193,707. |
| DuPont, “General Specifications for Kapton Polyimide Film,” Retrieved from Dupont: http://www2.dupont.com/Kapton/en_US/assets/downloads/pdf/Gen_Specs.pdf, pp. 1-7 (2012), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Dupont, “Pyralux® FR Coverlay, Bondply & Sheet Adhesive,” webpage, Retrieved from: www2.dupont.com/Pyralux/en_US/products/adhesives_films/FR/FR_films_html pp. 1-2 (2012), Submitted in parent application U.S. Appl. No. 16/193,707. |
| DuPont, “Pyralux® FR Copper-clad Laminate,” webpage, Retrieved from: www2.dupont.com/Pyraluxlen_US/ productsllaminate/FR/pyralux_fr.html, pp. 1-2 (2012), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Eberlein-Gonska et al., “The Incidence and Determinants of Decubitus Ulcers in Hospital Care: An Analysis of Routine Quality Management Data at a University Hospital,” Deutsches Arzteblatt International, 110(33-34):550-556, (2013), Submitted in parent application U.S. Appl. No. 16/193,707. |
| European Patent Office, ESSR issued on Aug. 22, 2014 for corresponding European Patent Application No. 117811061.4 (pp. 1-7) and pending claims (pp. 3-10) pp. 1-10, Submitted in parent application U.S. Appl. No. 16/193,707. |
| European Patent Office, Office Action issued on Jul. 13, 2015, for corresponding European Patent Application No. 11781061.4 (pp. 1-5) and claims (pp. 6-9) pp. 1-9, Submitted in parent application U.S. Appl. No. 16/193,707. |
| Extended European Search Report dated Aug. 19, 2016, in European Patent Application No. 16169670, Submitted in parent application U.S. Appl. No. 16/193,707. |
| Extended European Search Report dated Sep. 19, 2016, in European Patent Application No. 16166483.4, Submitted in parent application U.S. Appl. No. 16/193,707. |
| Extended European Search Report dated Mar. 13, 2017, in European Patent Application No. 16196899.5, Submitted in parent application U.S. Appl. No. 16/193,707. |
| Gabriel, “Compilation of the Dielectric Properties of Body Tissues at Rf and Microwave Frequencies Report,” Occupational and Environmental Health Directorate, (1996), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Physics in Medicine and Biology, 41:2251-69 (1996), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Gardiner et al., “Incidence of hospital-acquired pressure ulcers—a population-based cohort study,” International Wound Journal, 11(6):696-700 (2014), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Gershon et al., “SEM Scanner Readings to Assess Pressure Induced Tissue Damage,” Proceedings of the 17th Annual European Pressure Ulcer Advisory Panel (EPUAP) meeting, Stockholm, Sweden (2014), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Gonzalez-Correa et al., “Electrical bioimpedance readings increase with higher pressure applied to the measuring probe,” Physiology Measurement, 26:S39-S47 (2005), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Guihan et al., “Assessing the feasibility of subepidermal moisture to predict erythema and stage 1 pressure ulcers in persons with spinal cord injury: A pilot study,” Journal of Spinal Cord Medicine, 35(1):46-52 (2012), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Harrow, “Subepidermal moisture surrounding pressure ulcers in persons with a spinal cord injury: A pilot study,” Journal of Spinal Cord Medicine, 37(6):719-728 (2014), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Houwing et al., “Pressure-induced skin lesions in pigs: reperfusion injury and the effects of vitamin E,” Journal of Wound Care, 9(1):36-40 (2000), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Huang et al., “A device for skin moisture and environment humidity detection,” Sensors and Actuators B: Chemical, 206-212 (2008), Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Apr. 12, 2018, issued in International Patent Application No. PCT/US2018/016731, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Apr. 12, 2018, issued in International Patent Application No. PCT/US2018/016738, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Apr. 26, 2018, issued in International Patent Application No. PCT/US2018/016741, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Jul. 12, 2018, issued in International Patent Application No. PCT/US2018/016736, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Sep. 10, 2018, issued in International Patent Application No. PCT/US2018/038055, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Jan. 29, 2019 issued in International Patent Application No. PCT/US2018/061494, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Feb. 5, 2019, issued in International Patent Application No. PCT/US2018/064527, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated Feb. 11, 2019, issued in International Patent Application No. PCT/US2018/061497, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report dated May 29, 2019, issued in International Patent Application No. PCT/US2019/017226, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report and Written Opinion issued on Feb. 9, 2012 for International Patent Application No. PCT/US2011/035618, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report and Written Opinion issued on Jul. 22, 2016, for International Patent Application No. PCT/US2016/28515, Submitted in parent application U.S. Appl. No. 16/193,707. |
| International Search Report and Written Opinion issued on Jul. 26, 2016, for International Patent Application No. PCT/US2016/28515, Submitted in parent application U.S. Appl. No. 16/193,707. |
| Jan et al., “Local cooling reduces skin ischemia under surface pressure in rats: an assessment by wavelet analysis of laser Doppler blood flow oscillations,” Physiology Measurement, 33(10):1733-1745 (2012), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Jaskowski, “Evaluation of the Healing Process of Skin Wounds by Means of Skin Absolute Value of Electrical Impedance,” Dermatol. Mon.schr., 172(4):223-228 (1986), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Jiang et al., “Expression of cytokines, growth factors and apoptosis-related signal molecules in chronic pressure ulcer wounds healing,” Spinal Cord, 52(2):145-151 (2014), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Jiang et al., “Ischemia-Reperfusion Injury-Induced Histological Changes Affecting Early Stage Pressure Ulcer Development in a Rat model,” Ostomy Wound Management, 57:55-60 (2011), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Jiricka et al., “Pressure Ulcer Risk factors in an ICU Population,” American Journal of Critical Care, 4:361-367 (1995), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Kanai et al., “Electrical measurement of fluid distribution in legs and arms,” Medical Progress through Technology Journal, 12:159-170 (1987), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Kasuya et al., “Potential application of in vivo imaging of impaired lymphatic duct to evaluate the severity of pressure ulcer in mouse model,” Scientific Reports, 4:4173 (7 pages) (2014), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Lee, “CapSense Best Practices,” Application Note 2394, 1-10 (2007), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Loerakker et al., “The effects of deformation, ischemia, and reperfusion on the development of muscle damage during prolonged loading,” Journal of Applied Physiology, 111(4):1168-1177 (2011), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Loerakker et al., “Temporal Effects of Mechanical Loading on Deformation-Induced Damage in Skeletal Muscle Tissue,” Annual Review of Biomedical Engineering, 38(8):2577-2587 (2010), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Lyder et al., “Quality of Care for Hospitalized Medicare Patients at Risk for Pressure Ulcers,” Archives of Internal Medicine, 161:1549-1554 (2001), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Martinsen, “Bioimpedance and Bioelectricity Basics,” Elsevier Academic Press, Chapters 1 and 10 (2015), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Mathiesen et al., “Are labour-intensive efforts to prevent pressure ulcers cost-effective?” Journal of Medical Economics, 16(10):1238-1245 (2013), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Matthie et al., “Analytic assessment of the various bioimpedance methods used to estimate body water,” Journal of Applied Physiology, 84(5):1801-1816 (1998), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Miller et al., “Lymphatic Clearance during Compressive Loading,” Lymphology, 14(4):161-166 (1981), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Moore et al., “A randomised controlled clinical trial of repositioning, using the 30° tilt, for the prevention of pressure ulcers,” Journal of Clinical Nursing, 20:2633-2644 (2011), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Moore et al., “Pressure ulcer prevalence and prevention practices in care of the older person in the Republic of Ireland,” Journal of Clinical Nursing, 21:362-371 (2012), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Moore et al., “A review of PU prevalence and incidence across Scandinavia, Iceland and Ireland (Part I)”, Journal of Wound Care, 22(7):361-362, 364-368 (2013), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Mulasi, “Bioimpedance at the Bedside: Current Applications, Limitations, and Opportunities,” Nutritional Clinical Practice, 30(2):180-193 (2015), Submitted in parent application U.S. Appl. No. 16/193,707. |
| National Pressure Ulcer Advisory Panel et al., “Prevention and Treatment of Pressure Ulcers: Clinical Practice Guideline,” Cambridge Media, (2014), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Nixon et al., “Pathology, diagnosis, and classification of pressure ulcers: comparing clinical and imaging techniques,” Wound Repair and Regeneration, 13(4):365-372 (2005), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Nuutinen et al., “Validation of a new dielectric device to asses changes of tissue water in skin and subcutaneous fat,” Physiological Measurement, 25:447-454 (2004), Submitted in parent application U.S. Appl. No. 16/193,707. |
| O'Goshi, “Skin conductance; validation of Skicon-200EX compared to the original model, Skicon-100,” Skin Research and Technology, 13:13-18 (2007), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Oomens et al., “Pressure Induced Deep Tissue Injury Explained,” Annual Review of Biomedical Engineering, 42(2):297-305 (2015), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Scallan et al., “Chapter 4: Pathophysiology of Edema Formation,” Capillary Fluid Exchange: Regulation, Functions, and Pathology, 47-61 (2010), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Schultz et al., “Extracellular matrix: review of its role in acute and chronic wounds,” World Wide Wounds, 1-20 (2005), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Schwan, “Electrical properties of tissues and cells,” Advances in Biology and Medical Physics, 15:148-199 (1957), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Sener et al., “Pressure ulcer-induced oxidative organ injury is ameliorated by beta-glucan treatment in rats,” International Immunopharmacology, 6(5):724-732 (2006), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Sewchuck et al., “Prevention and Early Detection of Pressure Ulcers in Patients Undergoing Cardiac Surgery,” AORN Journal, 84(1):75-96 (2006), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Sprigle et al., “Analysis of Localized Erythema Using Clinical Indicators and Spectroscopy,” Ostomy Wound Management, 49:42-52 (2003), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Stekelenburg et al., “Deep Tissue Injury: How Deep is Our Understanding?” Archives of Physical Medicine Rehabilitation, 89(7):1410-1413 (2008), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Stekelenburg et al., “Role of ischemia and deformation in onset of compression-induced deep tissue injury MRI-based studies in a rat model,” Journal of Applied Physiology, 102:2002-2011 (2007), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Swisher et al., “Impedance sensing device enables early detection of pressure ulcers in vivo,” Nature Communications, 6:6575-6584 (2015), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Thomas et al., “Hospital-Acquired Pressure Ulcers and Risk of Death,” Journal of the American Geriatrics Society, 44:1435-1440 (1996), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Valentinuzzi et al., “Bioelectrical Impedance Techniques in Medicine. Part II: Monitoring of Physiological Events by Impedance,” Critical Reviews in Biomedical Engineering, 24(4-6):353-466 (1996), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Vangilder et al., “Results of Nine International Pressure Ulcer Prevalence Surveys: 1989 to 2005,” Ostomy Wound Management, 54(2):40-54 (2008), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Wagner et al., “Bioelectrical Impedance as a Discriminator of Pressure Ulcer Risk,” Advances in Wound Care, 9(2):30-37 (1996), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Wang, “Biomedical System for Monitoring Pressure Ulcer Development,” UCLA Electronic Theses and Dissertations, California, USA, pp. 1-123 (2013), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Watanabe et al., “CT analysis of the use of the electrical impedance technique to estimate local oedema in the extremities in patients with lymphatic obstruction,” Medical and Biological Engineering and Computing, 36(1):60-65 (1998), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Weiss, “Tissue destruction by neutrophils,” The New England Journal of Medicine, 320(6):365-76 (1989), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Extended European Search Report dated Oct. 25, 2019, in European Patent Application No. 19186393.5, Herewith. |
| Extended European Search Report dated Feb. 6, 2020, in European Patent Application No. 18748733.5, Herewith. |
| Extended European Search Report dated Feb. 10, 2020, in European Patent Application No. 18748512.3, Herewith. |
| Ford, “Hospice Wins Award for Innovation in Pressure Ulcer Prevention,” Nursing Times, downloaded and printed on Apr. 18, 2020, from https://www.nursingtimes.net/news/research-and-innovation/hospice-wins-award-for-innovation-in-pressure-ulcer-prevention-30-11-2018/ (2018), Herewith. |
| International Search Report dated Mar. 9, 2020, issued in International Patent Application No. PCT/US2019/055655, Herewith. |
| Moore et al., “SEM Scanner Made Easy,” Wounds International, pp. 1-6, available at www.woundsinternational.com (2018), Herewith. |
| Seibert et al., “Technical Expert Panel Summary Report: Refinement of a Cross-Setting Pressure Ulcer/Injury Quality Measure for Skilled Nursing Facilities, Inpatient Rehabilitation Facilities, Long-Term Care Hospitals, and Home Health Agencies,” RTI International Abt Associates, CMS Contract No. HHSM-500-2013-130151, 49 pp. (Aug. 2019), Herewith. |
| Supplementary Partial European Search Report dated Jan. 27, 2020, in European Patent Application No. 18747707, Herewith. |
| Extended European Search Report dated Nov. 19, 2019, in European Patent Application No. 19190000.0, Herewith. |
| Extended European Search Report dated Feb. 10, 2019, in European Patent Application No. 18748025.6, Herewith. |
| Extended European Search Report dated Jun. 24, 2020, in European Patent Application No. 18747707.0, Herewith. |
| Great Britain Search Report dated Apr. 27, 2020, in Great Britain Patent Applicaton No. GB2002889.0, Herewith. |
| Vowden et al., “Diabetic Foot Ulcer or Pressure Ulcer? That Is the Question,” The Diabetic Foot Journal, 18:62-66 (2015), Herewith. |
| Wang et al., “A Wireless Biomedical Instrument for Evidence-Based Tissue Wound Characterization,” Wireless Health, pp. 222-223 (2010), Herewith. |
| Zanibbi, “Pattern Recognition: An Overview,” downloaded from https://www.cs.rit.edu/˜rlaz/prec20092/slides/Overview.pdf, 30 pp. (2010), Herewith. |
| Bates-Jensen et al., “Subepidermal Moisture Detection of Pressure Induced Tissue Damage on the Trunk: The Pressure Ulcer Detection Study Outcomes,” Wound Repair and Regeneration, 25:502-511 (2017), Herewith. |
| Black et al., “Differential Diagnosis of Suspected Deep Tissue Injury,” International Wound Journal, 13(4):531-539 (2015), Herewith. |
| Great Britain Search Report dated Jun. 28, 2021, in Great Britain Patent Application No. GB2106848.1, Herewith. |
| Hou, “Section IV. Osteofascial Compartment Syndrom,” Limbs Trauma, 7:215-217 (2016), Herewith. |
| International Search Report dated Dec. 8, 2020, issued in International Patent Application PCT/US2020/051134, Herewith. |
| International Search Report dated Aug. 17, 2021, issued in International Patent Application PCT/US2021/023818, Herewith. |
| Moore et al., “Subepidermal Moisture (SEM) and Bioimpedance: A Literature Review of a Novel Method for Early Detection of Pressure-Induced Tissue Damage (Pressure Ulcers),” International Wound Journal, 14(2):331-337 (2016), Herewith. |
| Oliveira, “The Accuracy of Ultrasound, Thermography, Photography and Sub-Epidermal Moisture as a Predictor of Pressure Ulcer Presence—a Systematic Review,” RCSI, School of Nursing thesis (2015), Herewith. |
| Saxena, The Pocket Doctor: Obstetrics & Gynecology, pp. 76-77 (2017), Herewith. |
| Supplementary European Search Report dated Jul. 13, 2021, in European Patent Application No. 18887039, Herewith. |
| Supplementary European Search Report dated Oct. 1, 2021, in European Patent Application No. 19751130, Herewith. |
| Yang, Handbook of Practical Burn Surgery, p. 48 (2008), Herewith. |
| De Oliveira et al., “Sub-epidermal moisture versus tradition and visual skin assessments to assess pressure ulcer risk in surgery patients” Journal of Wound Care, 31(3):254-264 (2022), Herewith. |
| Extended European Search Report dated Mar. 17, 2022, in European Patent Application No. 19838240.0, Herewith. |
| Extended European Search Report dated May 24, 2022, in European Patent Application No. 19871332.3, Herewith. |
| Great Britain Search Report dated Feb. 9, 2022, in Great Britain Patent Application No. GB2118088.0, Herewith. |
| Great Britain Search Report dated Feb. 14, 2022, in Great Britain Patent Application No. GB2118092.2, Herewith. |
| International Search Report mailed May 13, 2022, issued in International Patent Application PCT/US2022/014913, Herewith. |
| Moore, “Using SEM (Sub Epidermal Moisture) Measurement for Early Pressure Ulcer Detection” Institute for Pressure Injury Prevention, WCICT 2017 (Jun. 20-21), Manchester, UK, 7 pp., available at www.pressureinjuryprevention.com/wp-content/uploads/2017/07/ipip_Moore_Sub_Epidermal_Moisture_notes.pdf (2017), Herewith. |
| Musa et al., “Clinical Impact of a Sub-Epidermal Moisture Scanner: What is the Real-World Use?,” J. Wound Care, 30(3):2-11 (2012) (JWC Proof), Herewith. |
| Truong et al., “Pressure Ulcer Prevention in the Hospital Setting Using Silicone Foam Dressings,” Cureus, 8(8):e730, pp. 1-6 (2016), Herewith. |
| Tur et al., “Topical Hydrogen Peroxide Treatment of Ischemic Ulcers in the Guinea Pig: Blood Recruitment in Multiple Skin Sites,” J. Am. Acad. Dermatol., 33:217-221 (1995), Herewith. |
| Vangilder et al., “Results of Nine International PRessure Ulcer Prevalence Surveys: 1989 to 2005,” Ostomy Wound Management, 54(2):40-54 (2008), Herewith. |
| De Oliveira et al., “Sub-epidermal moisture versus tradition and visual skin assessments to assess pressure ulcer risk in surgery patients,” Journal of Wound Care, 31(3):254-264 (2022), Mark Allen Group (pub.) (obtained online), Submitted in parent application U.S. Appl. No. 16/193,707. |
| Hamazoto et al., “Estimate of Burn Depth by Non-Invasive Capacitance Measurement,” Japan Soc. ME & BE, 42:266 (Jun. 2003), Herewith. |
| International Search Report mailed Aug. 2, 2022, issued in International Patent Application PCT/US2022/025508, Herewith. |
| International Search Report mailed Aug. 15, 2022, issued in International Patent Application PCT/US2022/019338, Herewith. |
| Pang et al., (eds.) Diagnosis and Treatment of Diabetes, China Press of Traditional Chinese Medicine (publisher), Beijing, China, pp. 466-468 (Oct. 2016), with English Translation, Herewith. |
| Extended European Search Report dated Feb. 1, 2023, in European Patent Application No. 22211200, Herewith. |
| Arimoto et al., “Non-Contact Skin Moisture Measurement Based on Near-Infrared Spectroscopy,” Applied Spectroscopy, 58(12):1439-1446 (2004), Herewith. |
| Extended European Search Report completed Nov. 7, 2023, in European Patent Application No. 23188775.3, Herewith. |
| Partial European Search Report dated Sep. 6, 2023, in European Patent Application No. 23188775.3, Herewith. |
| Ross et al., “Assessment of Sub-Epidermal Moisture by Direct Measurement of Tissue Biocapacitance,” Medical Engineering & Physics, 73:92-99 (Jul. 26, 2019), Herewith. |
| Supplementary Partial European Search Report dated Jan. 10, 2024, in European Patent Application No. 21782145, Herewith. |
| Avci et al., “Low-Level Laser (Light) Therapy (LLLT) in Skin: Stimulating, Healing, Restoring,” Seminars in Cutaneous Medicine and Surgery, 32(1)41-52 (Mar. 2013), Herewith. |
| Brunetti et al., “Validation of a sub-epidermal moisture scanner for early detection of pressure ulcers in an ex vivo porcine model of localized oedema,” J. Tissure Viability, 32(4)508-515 (available online Jul. 8, 2023), Herewith. |
| Byrne et al., “Sub epidermal moisture measurement and targeted SSKIN bundle interventions, a winning combination for the treatment of early pressure ulcer development,” Int. Wound J., 2022:1-13 (published online Nov. 25, 2022), Herewith. |
| Chan et al., “Using Wireless Measuring Devices and Tablet PC to Improve the Efficiency of Vital Signs Data Collection in Hospital,” 4 pp., 2014 IEEE International Symposium on Bioelectronics and Bioinformatics (IEEE ISBB 2014), Herewith. |
| Extended European Search Report dated Jun. 11, 2024, in European Patent Application No. 24158801.1, Herewith. |
| International Search Report mailed May 29, 2024, in International Patent Application PCT/US2023/074190, Herewith. |
| Lustig et al., “A maching learning algorithm for early detection of heel deep tissue injuries based on a daily history of sub-epidermal moisture measurements,” Int. Wound J., 2021:1-10 (published online Dec. 1, 2021), Herewith. |
| Partial European Search Report completed Mar. 27, 2024, in European Patent Application No. 23208591.0, Herewith. |
| Partial European Search Report completed Apr. 16, 2024, in European Patent Application No. 24151800.0, Herewith. |
| Supplementary European Search Report completed May 8, 2024, in European Patent Application No. 21782145, Herewith. |
| Visscher et al., “Face Masks for Noninvasive Ventilation: Fit, Excess Skin Hydration, and Pressure Ulcers,” Respiratory Care, 60(11):1536-1547 (Nov. 2015), Herewith. |
| Weber et al., “Remote Wound Monitoring of Chronic Ulcers,” IEEE Transactions on Information Technology in Biomedicine, IEEE Service Center, Los Alamitos, CA, vol. 13(2):371-377 (Mar. 1, 2010), Herewith. |
| U.S. Appl. No. 16/193,707, filed Nov. 16, 2018, which is abandoned. |
| U.S. Appl. No. 18/159,068, filed Jan. 24, 2023, which is pending. |
| U.S. Appl. No. 18/506,817, filed Nov. 10, 2023, which is pending. |
| U.S. Appl. No. 17/531,084, filed Nov. 19, 2021, which is pending. |
| U.S. Appl. No. 16/193,636, filed Nov. 16, 2018, which issued as U.S. Pat. No. 11,191,477 on Dec. 7, 2021. |
| U.S. Appl. No. 16/676,394, filed Nov. 6, 2019, which issued as U.S. Pat. No. 10,898,129 on Jan. 26, 2021. |
| U.S. Appl. No. 16/684,480, filed Nov. 14, 2019, which issued as U.S. Pat. No. 11,426,118 on Aug. 30, 2022. |
| Bluestein et al., “Pressure Ulcers: Prevention, Evalutaion, and Management,” Am. Fam. Physician, 78(10):1186-1194 (Nov. 15, 2008), Herewith. |
| De Oliveira et al., “The accuracy of ultrasound, thermography, photography and sub-epidermal moisture as a predictor of pressure ulcer presence—a systematic review” unsigned thesis submitted to the School of Postgraduate Studies, Faculty of Medicine and Health Sciences, Royal College of Surgeons in Ireland, 316 pp. (2015), retrieved from http://pstorage-rcsi-9048708668.s3.amazonaws.com/19329779/Theaccuracyofultrasoundthermographyphotographyandsubepi.pdf, Herewith. |
| Extended European Search Report completed Jan. 1, 2025, in European Patent Application No. 22767802.6, Herewith. |
| Extended European Search Report completed Jan. 3, 2025, in European Patent Application No. 24214401.2, Herewith. |
| Extended European Search Report completed Feb. 3, 2025, in European Patent Application No. 24214403.8, Herewith. |
| National Institue for Health and Care Excellence (“NICE”), “Pressure Ulcers: Prevention and Management,” Clinical Guideline, 11 pp. (Apr. 23, 2014), Herewith. |
| Reid et al., “Pressure Ulcer Prevention and Treatment: Use of Prophylactic Dressings” Chronic Wound Care Management and Research, 3:117-121 (Oct. 11, 2016), Herewith. |
| Stekelenburg et al., “Compression-Induced Tissue Damage: Animal Models,” in Pressure Ulcer Research, Springer-Verlag, Berlin/Heidelberg, pp. 187-204 (Jan. 1, 2005), Herewith. |
| Vapiwala et al., “Enhancing Career Paths for Tomorrow's Radiation Oncologists,” International Journal of Radiation: Oncology Biology Physics, 105(1):52-63 (May 22, 2019) (Pergamon Press), Herewith. |
| Great Britain Search Report dated Oct. 21, 2024, in Great Britain Patent Application No. GB2411677.4, Herewith. |
| Number | Date | Country | |
|---|---|---|---|
| 20200069241 A1 | Mar 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62693810 | Jul 2018 | US | |
| 62587337 | Nov 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16193707 | Nov 2018 | US |
| Child | 16677623 | US |
